

Not for distribution or release in the United States or to U.S. persons

ASX Announcement

12 June 2024

DESPATCH OF RETAIL ENTITLEMENT OFFER BOOKLET

Genetic Signatures Limited ACN 095 913 205 (ASX: GSS) (Genetic Signatures) is pleased to announce that it has today despatched a copy of the retail offer booklet (and accompanying personalised entitlement and acceptance form) (Retail Offer Booklet) to eligible retail shareholders of Genetic Signatures, which contains information about the retail component of Genetic Signatures' fully underwritten pro-rata accelerated non renounceable entitlement offer (Retail Entitlement Offer) of new fully paid ordinary shares (New Shares), details of which were announced to ASX on Tuesday, 6 June 2024 (Entitlement Offer).

Genetic Signatures Limited (ASX: GSS) (Genetic Signatures) is pleased to announce that it has today despatched a copy of the retail offer booklet (and accompanying personalised entitlement and acceptance form) (Retail Offer Booklet) to eligible retail shareholders of Genetic Signatures, which contains information about the retail component of Genetic Signatures' fully underwritten pro-rata accelerated non renounceable entitlement offer (Retail Entitlement Offer) of new fully paid ordinary shares (New Shares), details of which were announced to ASX on Tuesday, 4 June 2024 (Entitlement Offer).

A letter to retail shareholders who are ineligible to participate in the Entitlement Offer notifying them of the Entitlement Offer and their ineligibility to participate has also been despatched.

A copy of the attached Retail Offer Booklet is also accessible to eligible retail shareholders at <https://geneticsignatures.com/investors>.

Retail Entitlement Offer

The Retail Entitlement Offer opens today, Wednesday, 12 June 2024, and is expected to close at 5.00pm (Sydney, Australia time) on Monday, 1 July 2024. Application monies must be received prior to this time, in accordance with the Retail Offer Booklet and the personalised entitlement and acceptance form.

Shareholder enquiries

Eligible retail shareholders are encouraged to carefully read the Retail Offer Booklet for further details relating to the Retail Entitlement Offer. For further information in regard to the Retail Entitlement Offer, please do not hesitate to contact the Offer Information Line on 1300 737 760 (local call cost within Australia) or +61 2 9290 9600 (from outside Australia) at any time between 8.30am and 5.30pm (AEST), Monday to Friday.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr Neil Gunn
Director and
Interim Chief Executive Officer
neil.gunn@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.



Retail Offer Booklet

1 for 5.82 accelerated non-renounceable pro rata entitlement offer of New Shares at \$0.75 per New Share to raise approximately \$24 million (before costs)

Genetic Signatures Limited
(ACN 095 913 205)

The Retail Entitlement Offer closes at 5.00pm (AEST) on Monday, 1 July 2024 (unless extended or withdrawn)

The Entitlement Offer is lead managed and fully underwritten by Bell Potter Securities Limited and Taylor Collison Limited as Joint Lead Managers

IMPORTANT NOTICES:

If you are an Eligible Retail Shareholder, this is an important document that requires your immediate attention. This document and the accompanying personalised Entitlement and Acceptance Form should be read in their entirety.

This document is not a prospectus under the Corporations Act and has not been lodged with the ASIC. This document does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. Each recipient must make its own independent assessment of the Company before acquiring any Shares in the Company.

You should consult your stockbroker, solicitor, accountant or other professional adviser if you have any questions.

This Retail Offer Booklet may not be released to US wire services or distributed or released in the United States

IMPORTANT NOTICES

This Retail Offer Booklet is dated 12 June 2024.

Capitalised terms in this section have the meaning given to them in this Retail Offer Booklet. This Retail Offer Booklet has been issued by Genetic Signatures Ltd (ACN 095 913 205) (**Company**).

The Retail Entitlement Offer is made in accordance with section 708AA of the Corporations Act (as notionally modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84* and *ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73*). This Retail Offer Booklet does not contain all of the information which an investor may require to make an informed investment decision, nor does it contain all the information which would be required to be disclosed in a prospectus. The information in this Retail Offer Booklet does not constitute financial product advice and does not take into account your investment objectives, financial situation or particular needs.

This Retail Offer Booklet should be read in its entirety before you decide to participate in the Retail Entitlement Offer. This Retail Offer Booklet is not a prospectus or other disclosure document under the Corporations Act and has not been lodged with ASIC.

By paying for your New Shares through BPAY® (or in the case of Eligible Retail Shareholders in New Zealand, by electronic funds transfer) in accordance with the instructions on the Entitlement and Acceptance Form, you acknowledge that you have read this Retail Offer Booklet and you have acted in accordance with and agree to the terms of the Retail Entitlement Offer detailed in this Retail Offer Booklet.

Neither the Joint Lead Managers, any of their related bodies corporate and affiliates, nor any of their respective directors, officers, partners, employees, representatives or agents (together, the **Joint Lead Manager Parties**) have authorised, permitted or caused the issue or lodgement, submission, dispatch or provision of this Retail Offer Booklet and there is no statement in this Retail Offer Booklet which is based on any statement made by the Joint Lead Manager Parties. To the maximum extent permitted by law, the Joint Lead Manager Parties expressly disclaim all liabilities in respect of, and make no representations or warranties regarding, and take no responsibility for, any part of this Retail Offer Booklet other than references to their names and make no representation or warranty as to the currency, accuracy, reliability or completeness of this Retail Offer Booklet. The Joint Lead Managers do not guarantee any return or any particular rate of return on the New Shares offered under the Entitlement Offer, the performance of the Company generally, the repayment of capital from the Company or any particular tax treatment.

Foreign shareholders

This Retail Offer Booklet does not constitute an offer in any jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer. No action has been taken to permit a public offering of the New Shares in any jurisdiction outside of Australia. This Retail Offer Booklet and the accompanying Entitlement and Acceptance Form may not be distributed outside Australia except as may be permitted under section 5.16.

None of the information in this Retail Offer Booklet or the Entitlement and Acceptance Form that will accompany this Retail Offer Booklet when it is despatched to Eligible Retail Shareholders (as set out in the 'Key dates' section of this Retail Offer Booklet) constitutes an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Neither this booklet (or any part of it), the accompanying ASX announcement nor the Entitlement and Acceptance Form when that is available, may be released or distributed directly or indirectly, to any person in the United States.

This Retail Offer Booklet has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This Retail Offer Booklet does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this Retail Offer Booklet have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Definitions, currency and time

Defined terms used in this Retail Offer Booklet are contained in section 6.1. All references to time are to the Australian Eastern Standard Time (**AEST**), unless otherwise indicated.

Foreign exchange

All references to 'A\$' or '\$' are to Australian dollars, unless otherwise noted.

Taxation

The taxation consequences of any investment in New Shares will depend upon your particular circumstances. Potential investors must make their own enquiries concerning the taxation consequences of an investment in the Company. Applicants should consult their tax adviser for advice applicable to their individual needs and circumstances. The Company considers that it is not appropriate to give advice regarding the tax consequences of the Offer for each individual Shareholder and recommends that you consult your professional tax adviser.

The Company, to the maximum extent permitted by law, disclaims all liability with regard to taxation advice.

Privacy

The Company collects information about each Applicant provided on an Entitlement and Acceptance Form for the purposes of processing the Application and, if the Application is successful, to administer the Applicant's shareholding in the Company.

By submitting an Entitlement and Acceptance Form, you will be providing personal information to the Company (directly or through the Share Registry). The Company collects, holds and will use that information to assess your Application. The Company collects your personal information to process and administer your shareholding in the Company and to provide related services to you. The Company may disclose your personal information for purposes related to your shareholding in the Company, including to the Share Registry, the Company's related bodies corporate, agents, contractors and third-party service providers, including mailing houses and professional advisers, and to ASX and regulatory bodies. You can obtain access to personal information that the Company holds about you. To make a request for access to your personal information held by (or on behalf of) the Company, please contact the Company through the Share Registry.

No representations

No person is authorised to give any information or to make any representation in connection with the Retail Entitlement Offer which is not contained in this Retail Offer Booklet. Any information or representation in connection with the Retail Entitlement Offer not contained in the Retail Offer Booklet may not be relied upon as having been authorised by the Company or any of its officers. Except as required by law, and only to the extent so required, none of the Company, its related bodies corporate or any of its respective directors, officers, employees, agents, advisers or representatives, or any other person, warrants or guarantees the future performance of the Company or any return on any investment made pursuant to this Retail Offer Booklet.

Past performance

Investors should note that the Company's past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) the Company's future performance including the Company's future financial position or share price performance.

Future performance and forward-looking statements

This Retail Offer Booklet contains certain statements that constitute "forward-looking statements". These statements can be identified by the use of terminology such as "will", "anticipate", "believe", "expect", "project", "continue", "assume", "forecast", "estimate", "likely", "intend", "outlook", "should", "could", "may", "target", "plan" or comparable terminology. Indications of, and guidance on, future earnings, financial position, dividends and distributions and performance are also forward-looking statements, as are statements regarding the Company's intent, belief or current expectations with respect to the timetable, conduct and outcome of the Entitlement Offer and the use of proceeds thereafter, statements about the plans, objectives and strategies of the Company, statements about the industry and markets in which the Company operates, statements about the future performance of the Company's business and its financial condition, and forecasted economic indicators.

Such forward-looking statements are provided as a general guide only, should not be relied on as an indication or guarantee of future performance, and involve known and unknown risks, including (without limitation) uncertainties and other factors, many of which are beyond the control of the Company, its officers, employees, agents and advisors, that may cause the Company's actual results and performance to be materially different from any future results or performance expressed or implied in such statements. Forward-looking statements may also assume the success of the Company's business strategies. The success of any of these strategies is subject to uncertainties and contingencies beyond the Company's control, and no assurance can be given that any of the strategies will be effective or that the anticipated benefits from the strategies will be realised in the period for which the forward-looking statements may have been prepared or otherwise.

There can be no assurance that actual outcomes will not differ materially from the forward-looking statements in this Retail Offer Booklet. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecasted and their differences may be material. Refer to slides 28 to 34 of the Investor Presentation for a non-exhaustive summary of key risk factors.

Neither the Company or any other person gives any representation, warranty, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statement will occur.

To the maximum extent permitted by law, the Company, the Joint Lead Managers and their respective advisors, affiliates, related bodies corporate, directors, officers, partners, employees and agents disclaim any responsibility and undertake no obligation for the accuracy or completeness of any forward-looking statements whether as a result of new information, future events or results or otherwise. The Company and the Joint Lead Manager Parties disclaim any responsibility to update or revise any forward-looking statement to reflect any change in the Company's financial condition, status or affairs or any change in the events, conditions or circumstances on which a statement is based, except as required by Australian law.

Risks

An investment in New Shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company. The Company does not guarantee any particular rate of return or the performance of

the Company, nor does it guarantee or make any statement on any particular tax treatment.

Shareholders should refer to slides 28 to 34 of the Investor Presentation for a summary of key risk factors that may affect the Company and an investment in New Shares.

Trading of New Shares

The Company and the Joint Lead Manager Parties will have no responsibility and disclaim all liability (to the maximum extent permitted by law) to persons who trade New Shares they believe will be issued to them before they receive their holding statements, whether on the basis of confirmation of the allocation provided by the Company or the Share Registry or otherwise, or who otherwise trade or purport to trade New Shares in error or which they do not hold or are not entitled to.

If you are in any doubt, as to these matters you should first consult with your stockbroker, solicitor, accountant or other professional adviser.

Chairman's letter

12 June 2024

Dear Shareholder,

Genetic Signatures Limited – Accelerated Pro-Rata Non-Renounceable Entitlement Offer

On 4 June 2024, Genetic Signatures Limited (**Genetic Signatures** or the **Company**) announced that it is undertaking a capital raising of up to approximately \$30 million (before costs) through the issue of new fully paid ordinary shares (**New Shares**) at an offer price of \$0.75 per New Share (**Offer Price**), comprising:

- a placement of New Shares to Institutional Investors to raise up to approximately \$6 million (before costs) (**Placement**); and
- a fully underwritten pro rata accelerated non-renounceable entitlement offer to raise approximately \$24 million (before costs), whereby Eligible Shareholders will be invited to subscribe for 1 New Share for every 5.82 Existing Shares held on the record date (**Entitlement Offer**),

(together, the **Offer**). The Entitlement Offer comprises an institutional component (**Institutional Entitlement Offer**) and a retail component (**Retail Entitlement Offer**).

The Offer Price of \$0.75 per New Share represents:

- a 2.7% premium to the Company's closing price of \$0.73 on Thursday, 30 May 2024 (being the last trading day before the announcement of the Offer); and
- a 2.2% premium to the theoretical ex-rights price (**TERP**)¹ of \$0.734.

The proceeds of the Offer will be used to fund commercialisation of the Enteric Parasite product in the US, including new customer installations and establishment of manufacturing capability in the US. In addition, proceeds will be used to fund the next generation instrument development and new product development, general working capital and the costs of the Offer.

All Directors who are Eligible Shareholders intend to participate in the Entitlement Offer.

In addition to the Offer, Executive Director, Michael Aicher, has committed to subscribe for 66,666 New Shares to raise an additional \$50,000 (before costs) subject to receipt of shareholder approval under Listing Rule 10.11 to be sought at the Company's annual general meeting.

The Entitlement Offer is lead managed and fully underwritten by Bell Potter Securities Limited ACN 006 390 772 and Taylor Collison Limited ACN 008 172 450 as Joint Lead Managers. The Underwriting Agreement is on usual terms. Refer to section 5.7 for further details regarding the Underwriting Agreement.

Entitlement Offer

On behalf of the Board, I am pleased to invite Eligible Retail Shareholders to participate in the Retail Entitlement Offer. Under the Entitlement Offer, Eligible Shareholders are entitled to subscribe for 1 New Share for every 5.82 Existing Shares held at 7:00pm (AEST) on the Record Date of Thursday, 6 June 2024 (**Entitlement**) at the Offer Price. Approximately 32 million New Shares will be issued under

¹ TERP is the theoretical price at which Shares should trade after the ex-date for the Entitlement Offer. TERP is calculated by reference to the closing Share price on Thursday, 30 May 2024 of \$0.73 per share, being the last trading day prior to the announcement of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which Shares trade immediately after the ex-date of the Entitlement Offer will depend on many factors and may not be equal to TERP. TERP includes New Shares to be issued under the Placement.

the Entitlement Offer. New Shares will rank equally with existing Shares on issue in all respects from date of quotation.

The Retail Entitlement Offer closes at 5:00pm (AEST) on Monday, 1 July 2024 (unless extended or withdrawn). The Institutional Entitlement Offer closed on Wednesday, 5 June 2024 and, together with the Placement, has raised approximately \$21.5 million.

How to apply

Accompanying this Retail Offer Booklet is your personalised entitlement and acceptance form (**Entitlement and Acceptance Form**). It details your Entitlement and is to be completed in accordance with the instructions provided on the form and the instructions in section 3 of this Retail Offer Booklet. Your Entitlement and Acceptance Form can also be accessed and downloaded at www.investorserve.com.au.

You will require your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored or CHESS statements and you will need to pass the security requirements on the site. To log into InvestorServe, you will need to use your username and password. If you do not have one, please contact the Share Registry.

To participate, you must ensure that you have completed your Application by paying application monies (**Application Monies**) by BPAY® in accordance with the instructions set out in section 3 and your personalised Entitlement and Acceptance Form before 5:00pm (AEST) on Monday, 1 July 2024.

Eligible Retail Shareholders in New Zealand should follow the instructions on your Entitlement and Acceptance Form and payment instruction form to make payment via electronic funds transfer.

If you do not wish to take up any of your Entitlement, you do not have to take any action.

The Entitlement Offer is non-renounceable and therefore your Entitlement will not be tradeable on the ASX or any other exchange, cannot be sold, and is not otherwise transferable. This means that you will not receive any value for Entitlements you do not take up and your percentage shareholding in the Company will be reduced.

Shareholders in the United States are not eligible to participate in the Retail Entitlement Offer. Similarly, Shareholders (including custodians, trustees and nominees) who hold Shares on behalf of persons in the United States or are acting for the account or benefit of persons in the United States, are not eligible to participate in the Retail Entitlement Offer on behalf of those persons.


Further information and Application instructions

Further details of the Entitlement Offer, as well as the risks associated with investing in the Entitlement Offer, are set out in this Retail Offer Booklet (including in the ASX Announcements and the "Key Risks" section in slides 28 to 34 of the Investor Presentation), which you should read carefully and in their entirety.

For further information, please contact the Share Registry on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail to corporateactions@boardroomlimited.com.au.

On behalf of the Company, I invite you to consider this investment opportunity and thank you for your continued support.

Yours faithfully



Nick Samaras
Non-Executive Chairman
Genetic Signatures Limited

Summary of the Placement and Entitlement Offer

Entitlement Offer	
Ratio	1 New Share for every 5.82 Existing Shares held as at the Record Date
Offer Price	\$0.75 per New Share
Size (subject to rounding)	Approximately 32 million New Shares
Renounceability	The Entitlement Offer is non-renounceable and Entitlements cannot be traded, sold or transferred
Gross proceeds	Approximately \$24 million (before costs), comprising approximately \$15.5 million under the Institutional Entitlement Offer and approximately \$8.5 million under the Retail Entitlement Offer
Placement	
Offer Price	\$0.75 per New Share
Size	8 million New Shares
Gross proceeds	\$6 million
Post-offer position	
Number of Shares on issue following completion of the Placement and Entitlement Offer (subject to rounding)	Approximately 226,571,206 Shares

Offer key dates

Activity	Date
Announcement of the Placement and Entitlement Offer	Tuesday, 4 June 2024
Institutional Entitlement Offer / Placement launch	Tuesday, 4 June 2024
Results of Institutional Entitlement Offer and Placement announced and trading halt lifted	Thursday, 6 June 2024
Record Date for eligibility under the Entitlement Offer	7.00pm (AEST) on Thursday, 6 June 2024
Retail Offer Booklet lodged with the ASX	Wednesday, 12 June 2024
Retail Entitlement Offer opens	Wednesday, 12 June 2024
Settlement of New Shares issued under the Institutional Entitlement Offer and Placement	Wednesday, 12 June 2024
Allotment of New Shares under the Institutional Entitlement Offer and Placement	Thursday, 13 June 2024
New Shares issued under the Institutional Entitlement Offer and Placement commence trading on ASX	Thursday, 13 June 2024
Last day to extend Retail Entitlement Offer	Wednesday, 26 June 2024
Closing Date of Retail Entitlement Offer	5.00pm (AEST) on Monday, 1 July 2024
Results of Retail Entitlement Offer announced	Thursday, 4 July 2024
Settlement of New Shares issued under the Retail Entitlement Offer	Friday, 5 July 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Monday, 8 July 2024
New Shares issued under the Retail Entitlement Offer commence trading on ASX	Tuesday, 9 July 2024

The timetable above (and each reference to or to dates in this Retail Offer Booklet) is indicative only. The Company, in consultation with the Joint Lead Managers, reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act, the Listing Rules and other applicable laws. Any extension of the Closing Date will have a consequential effect on the allotment date of New Shares. The commencement of quotation of the New Shares is subject to confirmation from ASX.

The Company also reserves the right not to proceed with the Retail Entitlement Offer in whole or in part at any time prior to allotment and issue of the New Shares. In that event, the relevant Application Monies (without interest) will be returned in full to Applicants. Cooling-off rights do not apply to an investment in New Shares. You cannot withdraw your Application. Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer are encouraged to submit their Entitlement and Acceptance Form as soon as possible after the Retail Entitlement Offer opens.

Enquiries

If you have any doubt about whether you should participate in the Retail Entitlement Offer, you should seek professional financial advice from your stockbroker, solicitor, accountant or other suitably qualified professional financial adviser before making any investment decision. For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Share Registry on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail to corporateactions@boardroomlimited.com.au.

Table of Contents

1.	Summary of options available to you	10
2.	Overview of the Entitlement Offer	12
2.1	<i>Overview</i>	12
2.2	<i>Institutional Entitlement Offer and Placement</i>	12
2.3	<i>Retail Entitlement Offer</i>	12
2.4	<i>Ranking of New Shares</i>	13
3.	How to apply	14
3.1	<i>Your Entitlement</i>	14
3.2	<i>Options available to you</i>	14
3.3	<i>Taking up all of your Entitlement</i>	14
3.4	<i>Taking up only part of your Entitlement</i>	14
3.5	<i>Allowing your Entitlement to lapse</i>	14
3.6	<i>Payment</i>	15
3.7	<i>Payment by BPAY®</i>	15
3.8	<i>Entitlement and Acceptance Form is binding</i>	15
3.9	<i>Notice to nominees and custodians</i>	18
3.10	<i>Withdrawal of the Entitlement Offer</i>	18
3.11	<i>Risks</i>	18
3.12	<i>Further enquiries</i>	18
4.	ASX announcements and Investor Presentation	19
5.	Additional Information	68
5.1	<i>Eligibility of Retail Shareholders</i>	68
5.2	<i>Ineligible Shareholders</i>	68
5.3	<i>Allotment, trading and quotation</i>	69
5.4	<i>Reconciliation</i>	69
5.5	<i>Continuous disclosure</i>	69
5.6	<i>No cooling off rights</i>	69
5.7	<i>Underwriting of the Placement and Entitlement Offer</i>	70
5.8	<i>Rounding of Entitlements</i>	70
5.9	<i>Capital structure</i>	70
5.10	<i>Effect on control</i>	71
5.11	<i>Impact of underwriting</i>	71
5.12	<i>Not financial product or investment</i>	71
5.13	<i>Withdrawal of the Entitlement Offer</i>	71
5.14	<i>Privacy</i>	71
5.15	<i>Taxation</i>	72

5.16	<i>Foreign jurisdictions</i>	72
5.17	<i>Governing Law</i>	72
6.	Definitions and interpretation	74
6.1	<i>Defined terms</i>	74
6.2	<i>Interpretation</i>	75
7.	Corporate information	77

1. Summary of options available to you

If you are an Eligible Retail Shareholder, you may take one of the following actions:

- (a) take up all of your Entitlement (see section 2.2 for further information);
- (b) take up part of your Entitlement and allow the balance to lapse, in which case you will receive no value for the lapsed part of your Entitlement; or
- (c) do nothing, in which case your Entitlement will lapse and you will receive no value for the lapsed Entitlement.

If you are a retail Shareholder that is not an Eligible Retail Shareholder, you are an “**Ineligible Retail Shareholder**”. Ineligible Retail Shareholders are not entitled to participate in the Entitlement Offer.

Options available to you	Key considerations	For further information
Option One: Take up all of your Entitlement	<p>You may elect to take up your Entitlement and subscribe for New Shares at the Offer Price (see section 3 “How to Apply” for instructions on how to take up your Entitlement). The number of New Shares you are entitled to subscribe for is set out in your Entitlement and Acceptance Form.</p> <p>The Retail Entitlement Offer closes at 5.00pm (AEST) on Monday, 1 July 2024.</p> <p>The New Shares will be fully paid and rank equally in all respects with Existing Shares (including rights to dividends and distributions).</p>	See section 3.3
Option Two: Take up part of your Entitlement	<p>If you only take up part of your Entitlement, the part not taken up will lapse. The New Shares not subscribed for may be acquired by the Joint Lead Managers.</p> <p>If you do not take up your Entitlement in full, the balance not taken up will lapse and you will not receive any payment or value for that part of your Entitlement not taken up. You will have your percentage holding in the Company reduced as a result of dilution by the New Shares issued under the Entitlement Offer.</p>	See section 3.4
Option Three: Do nothing, in which case your Entitlement will lapse, and you will receive no value for your lapsed Entitlement	<p>If you do not take up your Entitlement, you will not be allocated New Shares and your Entitlement will lapse. Your Entitlement to participate in the Retail Entitlement Offer is non-</p>	See section 3.5

Options available to you	Key considerations	For further information
	<p>renounceable, which means it is non-transferrable and cannot be sold, traded on ASX or any other exchange, nor can it be privately transferred.</p> <p>If you do not take up your Entitlement you will not receive any payment or value for your Entitlement not taken up. You will have your percentage holding in the Company reduced as a result of dilution by the New Shares issued under the Entitlement Offer.</p>	

2. Overview of the Entitlement Offer

2.1 Overview

The Company intends to raise approximately \$24 million (before costs) under the Entitlement Offer via an offer of approximately 32 million New Shares (subject to rounding) at an Offer Price of \$0.75 per New Share. The Company will use the proceeds of the Entitlement Offer in accordance with the use of funds outlined in the Chairman's Letter.

The Entitlement Offer comprises the Institutional Entitlement Offer and the Retail Entitlement Offer (to which this Retail Offer Booklet relates).

The Entitlement Offer is underwritten by the Joint Lead Managers. Refer to section 5.7 for further details regarding the Underwriting Agreement.

Both the Institutional Entitlement Offer and the Retail Entitlement Offer are non-renounceable. Accordingly, Entitlements do not trade on the ASX nor can they be sold, transferred or otherwise disposed of. New Shares issued under the Retail Entitlement Offer are to be issued at the same price as New Shares issued under the Institutional Entitlement Offer. In addition, Shareholders' Entitlements under the Institutional Entitlement Offer and the Retail Entitlement Offer are calculated based on the same ratio.

2.2 Institutional Entitlement Offer and Placement

The Company has already raised approximately \$15.5 million under the Institutional Entitlement Offer, at the Offer Price. Concurrently with the Institutional Entitlement Offer, the Company undertook a Placement under which approximately 8 million New Shares were offered to new and existing Institutional Investors at the Offer Price per New Share, raising approximately \$6 million.

New Shares are expected to be issued under the Placement and Institutional Entitlement Offer on Thursday, 13 June 2024.

2.3 Retail Entitlement Offer

The Retail Entitlement Offer constitutes an offer to Eligible Retail Shareholders, who are invited to apply for 1 New Share for every 5.82 Existing Shares held on the Record Date. Please refer to sections 5.1 and 5.2 regarding your eligibility to participate in the Retail Entitlement Offer.

The Entitlement Offer is non-renounceable. Accordingly, Entitlements do not trade on the ASX, nor can they be sold, transferred or otherwise disposed of.

The Retail Entitlement Offer opens on Wednesday, 12 June 2024. The Retail Offer Booklet will be made available by that date, along with a personalised Entitlement and Acceptance Form, to Eligible Retail Shareholders. The Retail Entitlement Offer is expected to close at 5.00pm (AEST) on Monday, 1 July 2024.

The Retail Entitlement Offer is being made pursuant to section 708AA of the Corporations Act (as modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84* and *ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73*) which allows rights issues to be offered without a prospectus, provided certain conditions are satisfied.

As a result, the Retail Entitlement Offer is not being made under a prospectus and it is important for Eligible Retail Shareholders to read and understand the information on the Company and the Retail Entitlement Offer made publicly available by the Company, prior to taking up all or part of their Entitlement. In particular, please refer to the materials enclosed in section 4, the Company's interim and annual reports, other announcements made available at www.asx.com.au and all other parts of this Retail Offer Booklet carefully before making any decisions in relation to your Entitlement.

2.4 Ranking of New Shares

The New Shares issued under the Entitlement Offer will be fully paid and rank equally with Existing Shares. The rights attaching to the New Shares are set out in the Company's constitution and are regulated by the Corporations Act, Listing Rules and general law.

3. How to apply

3.1 Your Entitlement

Your Entitlement is calculated as 1 New Share for every 5.82 Existing Shares held on the Record Date. If you have more than one registered holding of Shares, you will have a separate Entitlement for each separate holding. A copy of your personalised Entitlement and Acceptance Form can be accessed and downloaded at www.investorserve.com.au.

3.2 Options available to you

Eligible Retail Shareholders may:

- (a) take up their Entitlement in full by the Closing Date (refer to section 3.3 for further information);
- (b) take up part of their Entitlement by the Closing Date, in which case the balance of the Entitlement would lapse (refer to section 3.4 for further information); or
- (c) do nothing and allow their Entitlement to lapse (refer to section 3.5 for further information).

The Retail Entitlement Offer is an offer to Eligible Retail Shareholders only. Ineligible Retail Shareholders may not take up any of their Entitlements.

The Company reserves the right to reject any Entitlement and Acceptance Form that is not correctly completed or that is received after the Closing Date.

The expected Closing Date for acceptance of the Retail Entitlement Offer is 5.00pm (AEST) on Monday, 1 July 2024 (however, that date may be varied by the Company, in accordance with the Listing Rules, applicable laws and the Underwriting Agreement).

3.3 Taking up all of your Entitlement

If you wish to take up all of your Entitlement, payment must be made by following the instructions on the personalised Entitlement and Acceptance Form. Please read the instructions carefully. Payment can be made via the method set out in section 3.7.

Payment must be received by no later than 5.00pm (AEST) on the Closing Date.

Refund amounts, if any, will be paid in Australian dollars. You will be paid by direct credit to the nominated bank account as noted on the share register as at the Closing Date. If the Share Registry does not have your bank account details, you will receive a letter requesting for those details. To enable Eligible Retail Shareholders to receive their refund by electronic funds transfer, Eligible Retail Shareholders are encouraged to update their bank details by contacting the Share Registry on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm (AEST) during Monday to Friday.

3.4 Taking up only part of your Entitlement

If you wish to take up only part of your Entitlement, payment must be made by following the instructions on the personalised Entitlement and Acceptance Form for the number of New Shares you wish to take up and making payment using the method set out in section 3.7 below. Payment must be received by no later than 5.00pm (AEST) on the Closing Date.

3.5 Allowing your Entitlement to lapse

If you do not wish to accept all or any part of your Entitlement, you do not need to take any further action and your Entitlement will lapse.

3.6 Payment

Payment should be made using BPAY®. If you are unable to pay using BPAY®, you can contact the Share Registry.

Eligible Retail Shareholders in New Zealand should follow the instructions on your Entitlement and Acceptance Form and payment instruction form to make payment via electronic funds transfer.

Cash payments or payments by cheque will not be accepted. Receipts for payment will not be issued.

The Company will treat you as applying for as many New Shares as your payment will pay for in full up to your Entitlement.

Any Application Monies received for more than your final allocation of New Shares will be refunded as soon as practicable after the close of the Retail Entitlement Offer. No interest will be paid to applicants on any Application Monies received or refunded.

3.7 Payment by BPAY®

For payment by BPAY®, please follow the instructions on the personalised Entitlement and Acceptance Form. You can only make payment via BPAY® if you are the holder of an account with any Australian financial institution that supports BPAY® Transactions.

If you are paying by BPAY®, please make sure you use the specific Biller Code and your unique Customer Reference Number (**CRN**) on your personalised Entitlement and Acceptance Form.

If you have multiple holdings and consequently receive more than one personalised Entitlement and Acceptance Form, when taking up your Entitlement in respect of one of those holdings only use the CRN specific to that holding. If you do not use the correct CRN specific to that holding your application will not be recognised as valid.

Please note that by paying by BPAY®:

- (a) you do not need to send your personalised Entitlement and Acceptance Form but are taken to make the declarations, representations and warranties referred to on that Entitlement and Acceptance Form and in section 3.8; and
- (b) if you do not pay for your full Entitlement, you are deemed to have taken up your Entitlement in respect of such whole number of New Shares which is covered in full by your Application Monies; and

It is your responsibility to ensure that your BPAY® payment is received by the Share Registry by no later than 5.00pm (AEST) on the Closing Date. You should be aware that your financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration in the timing of when you make payment. The Company shall not be responsible for any delay in the receipt of the BPAY® payment.

3.8 Entitlement and Acceptance Form is binding

A payment made through BPAY® or (or in the case of Eligible Retail Shareholders in New Zealand, by electronic funds transfer) constitutes a binding offer to acquire New Shares on the terms and conditions set out in this Retail Offer Booklet and, once paid, cannot be withdrawn. The Company's decision whether to treat an acceptance as valid and how to construe, amend or complete the Entitlement and Acceptance Form is final.

By making a payment by BPAY® (or in the case of Eligible Retail Shareholders in New Zealand, by electronic funds transfer) you will also be deemed to have acknowledged, represented and warranted on behalf of each person on whose account you are acting that:

- (a) you are (or the person on whose account you are acting is) an Eligible Retail Shareholder;
- (b) you acknowledge that you have read and understand this Retail Offer Booklet and your personalised Entitlement and Acceptance Form in their entirety;
- (c) you agree to be bound by the terms of the Retail Entitlement Offer, the provisions of this Retail Offer Booklet (and accompanying Entitlement and Acceptance Form), and the Company's constitution;
- (d) you authorise the Company to register you as the holder(s) of New Shares allotted to you;
- (e) you declare that all details and statements in the personalised Entitlement and Acceptance Form are complete and accurate;
- (f) you declare that you are over 18 years of age and have full legal capacity and power to perform all of your rights and obligations under the personalised Entitlement and Acceptance Form;
- (g) you acknowledge that once the Company receives any payment of Application Monies, you may not withdraw your application or funds provided except as allowed by law;
- (h) you agree to apply for and be issued up to the number of New Shares for which you have submitted payment of any Application Monies, at the Offer Price per New Share;
- (i) you authorise the Company, the Joint Lead Managers, the Share Registry and their respective officers or agents to do anything on your behalf necessary for New Shares to be issued to you, including to act on instructions of the Share Registry upon using the contact details set out in your personalised Entitlement and Acceptance Form;
- (j) you declare that you were the registered holder(s) at the Record Date of the Shares indicated on the personalised Entitlement and Acceptance Form as being held by you on the Record Date and you are an Eligible Retail Shareholder;
- (k) you acknowledge that the information contained in this Retail Offer Booklet and your personalised Entitlement and Acceptance Form is not investment advice nor a recommendation that New Shares are suitable for you given your investment objectives, financial situation or particular needs;
- (l) you acknowledge that this Retail Offer Booklet is not a prospectus, does not contain all of the information that you may require in order to assess an investment in the Company and is given in the context of the Company's past and ongoing continuous disclosure announcements to ASX;
- (m) you acknowledge the statement of risks in the Investor Presentation included in section 4, and that investments in the Company are subject to risk;
- (n) you acknowledge that none of the Company, the Joint Lead Managers, or their respective related bodies corporate and affiliates and their respective directors, officers, partners, employees, representatives, agents, consultants or advisers, guarantees the performance of the Company, the performance of the New Shares offered under the Entitlement Offer nor do they guarantee the repayment of capital;
- (o) you agree to provide (and direct your nominee or custodian to provide) any requested substantiation of your eligibility to participate in the Retail Entitlement Offer and of your holding of Shares on the Record Date;
- (p) you authorise the Company to correct any errors in your personalised Entitlement and Acceptance Form or other form provided by you;

- (q) you represent and warrant (for the benefit of the Company, the Joint Lead Managers and its respective related bodies corporate and affiliates) that you did not receive an invitation to participate in the Institutional Entitlement Offer either directly or through a nominee, are not an Ineligible Retail Shareholder and are otherwise eligible to participate in the Retail Entitlement Offer;
- (r) you acknowledge and agree that determination of eligibility of investors for the purposes of the Institutional Entitlement Offer and the Retail Entitlement Offer was determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the Company and/or the Joint Lead Managers, and each of the Company and the Joint Lead Managers and its respective related bodies corporate and affiliates disclaim any duty or liability (including for negligence) in respect of that determination and the exercise of that discretion to the maximum extent permitted by law;
- (s) you represent and warrant that the law of any place does not prohibit you from being given this Retail Offer Booklet and the personalised Entitlement and Acceptance Form, nor does it prohibit you from making an application for New Shares and that you are otherwise eligible to participate in the Retail Entitlement Offer;
- (t) you are an Eligible Retail Shareholder and are not in the United States and are not a person (including nominees or custodians) acting for the account or benefit of a person in the United States (or, in the event that you are acting for the account or benefit of a person in the United States, you are not participating in the Retail Entitlement Offer in respect of that person) and are not otherwise a person to whom it would be illegal to make an offer or issue New Shares under the Retail Entitlement Offer;
- (u) you understand and acknowledge that the New Shares have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction in the United States. Accordingly, you understand that the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws;
- (v) you are subscribing for or purchasing the New Shares outside the United States in an "offshore transaction" (as defined in Rule 902(h) under the US Securities Act) in reliance on Regulation S under the US Securities Act;
- (w) you have not and will not send any materials relating to the Retail Entitlement Offer to any person in the United States or any other country outside Australia and New Zealand or to any person (including nominees or custodians) acting for the account or benefit of a person in the United States;
- (x) you agree that if in the future you decide to sell or otherwise transfer the New Shares, you will only do so in transactions on ASX where neither you nor any person acting on your behalf knows, or has reason to know, that the sale has been pre-arranged with, or that the purchaser is, a person in the United States;
- (y) you are eligible under applicable securities laws to exercise Entitlements and acquire New Shares under the Retail Entitlement Offer; and
- (z) if you are acting as a nominee or custodian, each beneficial holder on whose behalf you are submitting the Entitlement and Acceptance Form is resident in Australia or New Zealand and (ii) is not in the United States.
- (aa) you agree to provide (and direct your nominee or custodian to provide) any requested substantiation of your eligibility to participate in the Retail Entitlement Offer and of your holding of Shares on the Record Date.

3.9 Notice to nominees and custodians

The Retail Entitlement Offer is being made to all Eligible Retail Shareholders. Nominees with registered addresses in the eligible jurisdictions, irrespective of whether they participate under the Institutional Entitlement Offer, may also be able to participate in the Retail Entitlement Offer in respect of some or all of the beneficiaries on whose behalf they hold Existing Shares, provided that the applicable beneficiary would satisfy the criteria for an Eligible Retail Shareholder.

Nominees and custodians should note in particular that the Retail Entitlement Offer is not available to:

- (a) beneficiaries on whose behalf they hold Existing Shares who would not satisfy the criteria for an Eligible Retail Shareholder;
- (b) an Eligible Shareholder who received an offer to participate in the Institutional Entitlement Offer (whether they accepted their Entitlement or not);
- (c) Shareholders who were ineligible to participate in the Institutional Entitlement Offer; or
- (d) Shareholders who are not eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

In particular, persons acting as nominees or custodians for other persons may not take up Entitlements on behalf of, or send any documents relating to the Retail Entitlement Offer to, any person in the United States or any person acting for the account or benefit of any person in the United States or other jurisdiction outside Australia or New Zealand.

The Company is not required to determine whether or not any registered holder is acting as a nominee or custodian or the identity or residence of any beneficial owners of Shares. The Company is not able to advise on foreign laws.

For the avoidance of doubt, subject to the consent of the Joint Lead Managers, the Company reserves the right (in its absolute sole discretion) to reduce the number of New Shares allocated to Eligible Retail Shareholders, or persons claiming to be Eligible Retail Shareholders, if their claims prove to be overstated or they fail to provide information to substantiate their claims.

The Company also reserves the right to reject any acceptance of an Entitlement that it believes comes from a person who is not eligible to accept an Entitlement.

3.10 Withdrawal of the Entitlement Offer

Subject to applicable law, the Company reserves the right to withdraw the Entitlement Offer at any time before the issue of New Shares, in which case the Company will refund any Application Monies already received in accordance with the Corporations Act and will do so without interest being payable to applicants.

3.11 Risks

Eligible Retail Shareholders should be aware that an investment in the Company, including taking up your Entitlement, involves risks. The key risks identified by the Company are summarised in slides 28 to 34 of the Investor Presentation included in section 4, but these are not an exhaustive list of the risks associated with an investment in the Company.

3.12 Further enquiries

If you have not received or you have lost your personalised Entitlement and Acceptance Form, or have any questions regarding the Retail Entitlement Offer, please contact the Company on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 9:00am and 5:00pm (AEST) during Monday to Friday, before the Closing Date. If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional adviser.

4. ASX announcements and Investor Presentation

This Retail Offer Booklet is dated Wednesday, 12 June 2024. The Investor Presentation and Launch Announcement are current as at Tuesday, 4 June 2024 and the Institutional Results Announcement is current as at Thursday, 6 June 2024.

This Retail Offer Booklet remains subject to change without notice. To the maximum extent permitted by law, the Company and its advisors, affiliates, related bodies corporate, directors, officers, partners, employees and agents disclaim any responsibility and undertake no obligation for the accuracy or completeness of any forward-looking statements whether as a result of new information, future events or results or otherwise. The Company disclaims any responsibility to update or revise any forward-looking statement to reflect any change in the Company's financial condition, status or affairs or any change in the events, conditions or circumstances on which a statement is based, except as required by Australian law.

There are additional ASX announcements that have been made by the Company and which may be made throughout the Entitlement Offer Period that may be relevant in your consideration of whether to take part in the Entitlement Offer. Therefore, it is prudent you check whether any future ASX announcements have been made by the Company before submitting an Application.

Not for distribution or release in the United States or to U.S. persons

ASX Announcement

4 June 2024

GENETIC SIGNATURES ANNOUNCES ~\$30 MILLION EQUITY RAISING

Genetic Signatures Limited ACN 095 913 205 (“GSS” or the “Company”) is pleased to announce that it has launched an equity raising (**Offer**) through a placement to institutional investors (**Placement**) and a fully-underwritten pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**).

Key highlights

- The Company is seeking to raise approximately ~A\$30 million to commercialise the Enteric Parasite product in the US and strengthen its balance sheet
- As announced concurrently with the equity raising, the Company has received FDA clearance for its *EasyScreen*TM Gastrointestinal Parasite Detection Kit in the US and appointed current MD of Roche Diagnostics Australia, Allison Rossiter as CEO, commencing September 2024
- The Offer will comprise an institutional placement to raise ~A\$6 million (before costs) and a fully underwritten accelerated non-renounceable pro rata entitlement offer to eligible Genetic Signatures shareholders to raise ~A\$24 million (before costs)
- Funds raised under the Offers will be applied towards supporting the US commercialisation of the Enteric Parasite product in the US, including new customer installations and establishment of manufacturing capability in the US. In addition, proceeds will be used to fund the next generation instrument development, new product development and general working capital
- All eligible Directors of GSS intend to participate in the Entitlement Offer
- Bell Potter Securities Limited and Taylor Collison Limited are acting as joint lead managers to the Offers and underwriters to the Entitlement Offer

The Offers

Genetic Signatures has today announced a capital raising of ~A\$30 million comprising the Placement and fully underwritten Entitlement Offer.

The Offers are expected to result in the issue of approximately 40 million new fully paid ordinary shares in Genetic Signatures (**New Shares**), representing approximately 21.5% of Genetic Signatures’ existing fully paid ordinary shares (**Shares**) on issue. Each New Share issued under the Placement and the Entitlement Offer will rank equally with existing shares in the Company on issue.

Placement

The Placement involves the offer of approximately 8 million New Shares to institutional investors at an issue price of A\$0.75 per New Share to raise ~A\$6 million (before costs), representing 4.3% of Genetic Signatures current issued capital. The New Shares under the Placement will be issued pursuant to the Company's available placement capacity under ASX Listing Rule 7.1 which has been upsized by a 'supersize' placement waiver granted by ASX and accordingly no shareholder approval is required in connection with the Placement.

The issue price of A\$0.75 per New Share represents a 2.7% premium to the last traded price of the Company's ordinary shares on ASX of A\$0.73 and a 11.6% premium to the 5-day volume weighted average price of the Genetic Signatures ordinary shares as traded on the Australian Securities Exchange (ASX) of A\$0.67 over the period up to and including 30 May 2024.

The Placement is being conducted today, Tuesday, 4 June 2024. Settlement is expected to occur on Wednesday, 12 June 2024 with issue of the New Shares expected to occur on or around Thursday, 13 June 2024.

In addition to the Offer, Executive Director, Michael Aicher, has committed to subscribe for 66,666 New Shares to raise an additional \$50,000 (before costs) subject to receipt of shareholder approval under Listing Rule 10.11 to be sought at the Company's annual general meeting.

The Entitlement Offer

The Entitlement Offer which seeks to raise ~A\$24 million (before costs) will consist of a 1-for-5.82 fully underwritten accelerated pro-rata non renounceable entitlement offer, including:

- an institutional entitlement offer to raise ~A\$15.5 million (before costs) (**Institutional Entitlement Offer**); and
- a retail entitlement offer to raise ~A\$8.5 million (before costs) (**Retail Entitlement Offer**).

Under the Entitlement Offer, eligible shareholders are invited to subscribe for 1 New Share for every 5.82 Shares held as at 7:00pm (Sydney, Australia time) on Thursday, 6 June 2024 (**Record Date**). Fractional entitlements will be rounded up to the nearest whole share. All New Shares in the Entitlement Offer will be issued at a price of A\$0.75 per New Share (being the same as the issue price under the Placement) which represents:

- a 2.7% premium to the last close price of A\$0.73 on Thursday, 30 May 2024; and
- a 2.2% premium to the theoretical ex-rights price (TERP)¹ of 0.734.

Entitlements cannot be traded on the ASX or transferred. Eligible shareholders who do not

¹ TERP is the theoretical price at which Shares should trade after the ex-date for the Entitlement Offer. TERP is calculated by reference to the closing Share price on Thursday, 30 May 2024 of \$0.73 per share, being the last trading day prior to the announcement of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which Shares trade immediately after the ex-date of the Entitlement Offer will depend on many factors and may not be equal to TERP. TERP includes New Shares to be issued under the Placement.

take up their entitlements under the Entitlement Offer in full or in part, will not receive any value in respect to those entitlements not taken up.

Bell Potter Securities Limited and Taylor Collison Limited are acting as joint lead managers to the Offers and underwriters to the Entitlement Offer. The Entitlement Offer is fully underwritten.

Genetic Signatures' Shares will remain in a trading halt until the commencement of trading on Thursday, 6 June 2024 pending completion of the Placement and the Institutional Entitlement Offer.

Institutional Entitlement Offer

Eligible institutional shareholders will be invited to participate in the Institutional Entitlement Offer, which is being conducted today, Tuesday, 4 June 2023. Eligible institutional shareholders can choose to take up all, part or none of their entitlements under the Entitlement Offer.

Entitlements not taken up by institutional shareholders cannot be traded on market or transferred. Entitlements not taken up by eligible institutional shareholders, and institutional entitlements that would otherwise have been offered to ineligible institutional shareholders, will be offered to eligible institutional shareholders at the Offer price.

Retail Entitlement Offer

Eligible retail shareholders with a registered address in Australia or New Zealand will be invited to participate in the Retail Entitlement Offer. The Retail Entitlement Offer will open on Wednesday, 12 June 2024 and closes at 5:00pm (Sydney, Australia time) on Monday, 1 July 2024 (**Retail Offer Period**), unless otherwise extended by the Company in accordance with the ASX Listing Rules.

Further details about the Retail Entitlement Offer will be set out in the retail offer booklet, which Genetic Signatures expects to lodge with the ASX on Wednesday, 12 June 2024 (**Retail Offer Booklet**).

Use of proceeds received under the Offers

The funds raised under the Offers (after deduction of the costs associated with the Offers) are expected to be used to support the US commercialisation of the Enteric Parasite product in the US, including new customer installations and establishment of manufacturing capability in the US. In addition, proceeds will be used to fund the next generation instrument development, new product development and general working capital.

Offer Timetable

Event	Time (Sydney time) / Date
Back-to-back trading halt	Friday, 31 May 2024
Offer announcement and Placement and Institutional Entitlement Offer opens	Tuesday, 4 June 2024
Announcement of results of Placement and Institutional Entitlement Offer	Thursday, 6 June 2024
Trading in Genetic Signatures shares resumes on an ex-entitlement basis	Thursday, 6 June 2024
Record Date for determining entitlement for the Entitlement Offer	7.00 pm AEST Thursday, 6 June 2024
Retail Offer Booklet made available and retail Entitlement Offer opens	Wednesday, 12 June 2024
Settlement of Placement and Institutional Entitlement Offer	Wednesday, 12 June 2024
Allotment of New Shares issued under the Placement and Institutional Entitlement Offer	Thursday, 13 June 2024
Normal trading of New Shares issued under the Placement and Institutional Entitlement Offer	Friday, 14 June 2024
Retail Entitlement Offer closing date	5pm AEST Monday, 1 July 2024
Settlement of Retail Entitlement Offer	Friday, 5 July 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Monday, 8 July 2024
Normal trading of New Shares issued under the Retail Entitlement Offer	Tuesday, 9 July 2024

Note: The timetable above is indicative only and may be subject to change. All times and dates refer to Sydney time. GSS reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws. In particular, GSS reserves the right to extend the closing date of the Retail Entitlement Offer, to accept late applications under the Entitlement Offer (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice. Any extension of the closing date will have a consequential effect on the issue date of New Shares under the Entitlement Offer.

If you have any questions in respect of the Entitlement Offer, please call the Company's Registry, Boardroom Pty Limited, on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) at any time from 9:00am to 5:00pm (Sydney time) Monday to Friday during the Retail Offer Period, or consult your broker, accountant, legal, financial, tax or other professional adviser.

Additional information

Additional information in relation to the Offers and the Company can be found in the investor presentation released to the ASX simultaneously with this announcement, which contains important information, including a breakdown of sources and uses of funds, key risks and foreign selling restrictions with respect to the Offer as well as a summary of the

underwriting agreement in connection with the Entitlement Offer.

Nothing contained in this announcement constitutes investment, legal, tax or other advice. Investors should seek appropriate professional advice before making any investment decision. All amounts are in Australian dollars unless otherwise indicated.

An Appendix 3B for the proposed issue of New Shares will be released in conjunction with this announcement. Further details on the fees payable to the Joint Lead Manager are set out in the Appendix 3B.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr Neil Gunn
Director and
Interim Chief Executive Officer
neil.gunn@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

IMPORTANT NOTICES

This announcement is for information purposes only to assist interested parties in making their own evaluation with respect to the Offer and should not be read or understood as an offer, invitation, solicitation, inducement or recommendation to subscribe, buy or sell Genetic Signatures securities in any jurisdiction. No such offering of securities shall be made except by means of a prospectus, disclosure document or other offering document meeting the requirements of the Corporations Act or an exemption therefrom. The Offer

described herein has not been and will not be registered under the securities laws of any other jurisdiction. This announcement will not form any part of any contract or commitment for the acquisition of Genetic Signatures securities. This announcement is not a prospectus, product disclosure statement or other disclosure document under Australian law or any other law. It will not be lodged with the Australian Securities and Investments Commission. Nothing contained in this announcement constitutes financial product, investment, legal, tax or other advice or recommendation. It does not take into account the investment objectives, financial situation or needs of any particular investor. You should consult your own legal, financial, investment, tax or other advisors as to the legal and related matters described herein and consider the appropriateness of the information in this presentation having regard to your own investment objectives, financial situation and needs when deciding if an investment is appropriate. By accepting this announcement, you confirm that you are not relying upon the information contained herein nor any information presented or research undertaken by the Joint Lead Managers.

The release, publication or distribution of this announcement (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe restrictions and should seek your own advice on restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares to be offered and sold in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933 (the **US Securities Act**) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless they are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

FORWARD LOOKING STATEMENTS

This announcement contains certain "forward-looking statements" including but not limited to projections, that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Such forward-looking statements include statements regarding the timetable, conduct and outcome of the Offer and the use of proceeds thereof, statements about the plans, objectives and strategies of the management of Genetic Signatures, statements about the industry and the markets in which Genetic

Signatures operates and statements about the future performance of the Genetic Signatures businesses.

Indications of, and guidance or outlook on, future earnings or financial position or performance, future earnings and distributions are also forward-looking statements.

You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption to equity and capital markets. Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. This includes statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Genetic Signatures and its subsidiaries, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Forward-looking statements may also assume the success of the Genetic Signatures business strategies. The success of any of these strategies is subject to known and unknown risks, uncertainties and contingencies beyond Genetic Signatures' control, and no assurance can be given that any of the strategies will be effective or that the anticipated benefits from the strategies will be realised in the period for which the forward-looking statements may have been prepared or otherwise. Refer to the key risks in Appendix B of the Investor Presentation for a non-exhaustive summary of certain key business, offer and general risk factors that may affect Genetic Signatures and its subsidiaries.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of the Australian and global economic environment and capital market conditions and other risk factors set out in the Investor Presentation. Investors should consider the forward-looking statements contained in this announcement in light of those risks and disclosures. The forward-looking statements are based on information available to Genetic Signatures as at the date of this announcement.

No representation, warranty, or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Genetic Signatures or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur.

Actual operations, results, performance, production targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Except as required by law or regulation (including the ASX Listing Rules), none of Genetic Signatures, its representatives or advisers undertakes any obligation to provide any additional or updated information in respect of any statements made including forward-looking statements, whether as a result of a change in expectations or assumptions, conditions, new information, future events or results or otherwise

Certain financial measures included in this announcement are ‘non-IFRS financial information’ under ASIC Regulatory Guide 230 : ‘Disclosing non IFRS financial information’ and also ‘non-GAAP financial measures’ within the meaning of Regulation G under the US Securities Exchange Act of 1934 as amended, and are not recognised under Australian Accounting Standards (AAS) (and International Financial Reporting Standards (IFRS)). This non-IFRS financial information and non- GAAP financial measures are not measures of financial performance in accordance with AAS or IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under AAS and IFRS. Such-non IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS and may therefore not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although Genetic Signatures believes these non-IFRS financial information/non-GAAP financial measures provide useful information to investors in measuring the financial performance and condition of its business, and provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial information/non-GAAP financial measures to investors. The non-IFRS financial information/non-GAAP financial measure are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining the non-IFRS financial information/non-GAAP financial measures. Investors are cautioned not to place undue reliance on these non-IFRS financial information/non-GAAP financial measures.



FDA Clearance and Capital Raising Presentation

4 June 2024

Not for release to US wire services or distribution in the United States

Disclaimer



This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It provides general background information about the Company's activities current as at the date of this presentation. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future.

The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any or contract or investment decision. This presentation may not be released to US wire services or distributed in the United States. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or in other jurisdictions where it would be illegal. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable US state securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable US state securities laws.

The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness.





Proprietary 3base® technology underpinning an automated diagnostic workflow

- A differentiated approach to **molecular diagnostic** assays for infectious diseases
- Detects a wide range of clinically relevant targets, **in one test – Syndromic Testing**
- Uniform sample processing conditions regardless of sample type allowing for a **simplified workflow**
- Robust pipeline with **multiple products cleared for sale** in Australia and Europe
- Over **5 million patients** have been tested to date in multiple markets

FDA clearance received for EasyScreen™ Gastrointestinal Parasite Detection

- FDA clearance for *EasyScreen™* Gastrointestinal Parasite Detection Kit has been received. This provides the broadest molecular syndromic test for 8 clinically relevant GI parasites
- Currently no stand-alone FDA cleared parasite molecular test which detects more than 4 parasites
- Potential to displace traditional testing which is manual, slow, labour intensive and unreliable

US product launch and market size

- Company to immediately begin commercialising in US – primary target to convert pre-qualified sites
- Existing reimbursement coding in place allowing potential for high gross margins
- Est. 5.5m first generation manual Enteric Parasite tests p.a. in the US – TAM of > \$A500M p.a.¹
- Targeting to achieve 40% market share in US within 5 years

¹Assumes an indicative selling price of US\$60 per test displacing existing Ova & Parasite (O&P) testing estimated at over 5.5 million p.a. Assumptions of the number of tests are presented on slide 11.



New CEO announced adding to an experienced team commercialising molecular diagnostic tests

- Allison Rossiter to serve as CEO commencing September 2024
- Former MD of Roche Diagnostics Australia. Extensive experience in commercialisation of molecular diagnostics products globally, having held senior executive roles within Roche in the United Kingdom, the United States and Canada
- Supported by highly experienced sales and field services team in the United States
- Interim CEO Neil Gunn to return as Non-Executive Director of the Company

Significant news flow and catalysts expected in the near term

- Initial target to convert pre-qualified customer experience sites to initial customers - First US revenue anticipated early FY25
- Multiple contracts anticipated with large US diagnostic laboratories early FY25
- Updated Respiratory Kit authorised for supply by the TGA in April 2024 – significant positive impact on Australian sales expected
- Sales and channel partners in the UK and EMEA markets
- Further R&D initiatives for new products and technology improvements

Seeking to raise \$30m to support US launch and other R&D initiatives

- A\$30.0m capital raising comprising a A\$6.0m Placement and a fully underwritten 1 for 5.82 accelerated non-renounceable entitlement offer to raise A\$24.0m at A\$0.75 per share
- Funds raised to support extensive commercialisation in the US of EasyScreen and development of NextGen Instrument
- Post capital raising pro-forma cash balance of A\$50.3m¹ with all commercialisation, regulatory and R&D expenditure fully funded – including development of next generation instrument

¹ 31 March 2024 cash balance of A\$20.3m, excludes offer costs



A highly experienced global molecular diagnostics executive to drive global commercialisation for Genetic Signatures

- Ms Rossiter has extensive global experience in the diagnostics industry. Since 2003 she has held several senior executive roles with largest diagnostics company in the world by revenue, Roche Diagnostics.
- Ms Rossiter was previously the Managing Director of Roche Diagnostics in Australia.
- Ms Rossiter has had direct executive responsibility for sales and marketing efforts in the United States, United Kingdom and Canada.



Allison Rossiter incoming CEO of Genetic Signatures said: *“It is an incredibly exciting time for GSS and I am honoured to take on this role at such a pivotal time for the company and the employees.”*



US Commercial Rollout for Gastrointestinal Parasite Test





EasyScreen™ Gastrointestinal Parasite Detection Kit cleared for sale by the FDA

The product addresses an unmet need

- Broadest molecular syndromic test for 8 clinically relevant GI parasites
- No current stand-alone FDA cleared molecular test detects >4 parasites

Product leverages 3base™ advantages

- Enables simpler workflow for all targets than traditional PCR

~5.5 million 1st Generation tests conducted in the US / year

- Traditional tests are manual, slow, labour intensive & unreliable
- Current testing is not profitable for pathology laboratories

Molecular reimbursement code already in place

- Estimated TAM of > \$A500M¹ p.a
- Higher reimbursement rate than traditional microscopic tests
- Targeting to achieve 40% market share in US market within 5 years

¹Assumes an indicative selling price of US\$60 per test displacing existing Ova & Parasite (O&P) testing estimated at over 5.5 million p.a. Assumptions of the number of tests are presented on slide 11.



**United States
FDA 510(k) cleared**



EasyScreen™ Gastrointestinal Parasite Detection Kit

8 parasites detected



Giardia spp.



Cryptosporidium spp.



Entamoeba histolytica



Cyclospora cayetanensis



Dientamoeba fragilis



Blastocystis hominis



Enterocytozoon bienersi

Encephalitozoon intestinalis



Higher reliability

Testing is controlled and reproducible.



Improved sensitivity and specificity

Traditional testing have < 55% sensitivity



Increased pathogen coverage

Testing for 8 most clinically relevant pathogens



Reduced patient burden

Single sample required compared to multiple samples for microscopic testing



Reduced labour

Many automated steps reducing labour costs, handling, turnaround and training




Time efficient

Reduction in time to results from days to a few hours enabling rapid treatment and improved patient outcomes




- Estimated ~65m GI parasitic infections per annum in US
- An estimated 9m patients¹ with GI parasitic infections seek medical attention in the United States
- Of this there are approximately 5.5 million microscopy O&P tests performed²
- Targeting to displace 40% of O&P testing
- Reduced patient sample burden with molecular test may increase the addressable market over time



¹Estimated GI infections per year in the United States associated with parasites. Schmidt MA, Groom HC, Rawlings AM, Mattison CP, Salas SB, Burke RM, et al. Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. Emerg Infect Dis. 2022;28(11):2234-2242.





²Based on GSS analysis and external data sources detailed on slide 11.



Four distinct customer segments – all targets



*EP005 = EasyScreen™ Gastrointestinal Parasite Detection Kit

Target segments	GI parasite testing requirements	Potential TAM = 5.5 m tests	Share of targeted 2.2m EP005* tests by segment	Potential customers
Large commercial reference labs	High volume LabCorp / Quest = >1500 tests / day Others ~100-300 tests / day	1.65 million 30% of TAM	 50%	<ul style="list-style-type: none"> • LabCorp • Quest • Sonic Health • BioReference Laboratories • Clinical Reference Laboratory
IDN / core labs (large hospitals)	Low to medium volume, Some sites high volume Average ~50-100 tests / day	3.03 million 55% of TAM	 32%	<ul style="list-style-type: none"> • Kaiser Permanente • Baylor Scott and White • Northwell Health • Cleveland Health Clinic • Sutter Health
Specialty reference labs	Medium to high volume Average ~40-100 tests / day	0.28 million 5% of TAM	 12%	<ul style="list-style-type: none"> • ARUP Laboratories • Mayo Clinic • Wadsworth Center • University of Nebraska • Emory Medical Laboratory
Independent hospitals	Low to medium volume, Average ~20-40 tests / day	0.55 million 10% of TAM	 6%	<ul style="list-style-type: none"> • Scripps Laboratories • Sharp Laboratories • John Hopkins • Tampa General • Henry Beaumont

Target size and TAM modelled from various data sources listed here

- Morningstar Credit Ratings, LLC 16th October 2018. Credit Comparison: LabCorp (BBB+, stable) vs. Quest (BBB+, stable). [Link](#)
- Laboratory Economics, Volume 18, No. 3. March 2023. Jondavid Klipp. [Link](#)
- Genetic Signatures Market Survey Insights. March 2023
- DeciBio ID DX-Book 2022

- Definitive Healthcare, Healthcare Insights, How many IDNs are in the U.S.?, 21/4/23. [Link](#)
- American Hospital Association, Fast Facts. U.S. Health Systems. 2023. [Link](#)
- Lab Florida. Types of Labs in U.S. Medical Diagnostics. Accessed on 13/9/23. [Link](#)
- Australian Medicare Benefits Schedule Book (MBS). [Link](#)



Conventional process

Highly manual and complex workflow, slow time to result, high labour and time costs with lower reimbursement will drive adoption of cleared IVD molecular tests.

There are high costs to maintain IVD accreditation for an individual lab, and the increased regulation of Lab Developed tests will encourage adoption of cleared IVD tests.

5.5 Million
tests per year

O&P
Microscopy
testing

Lab
Developed
Tests

Genetic Signatures solution FDA cleared






FDA Cleared
In Vitro
Diagnostic tests

Genetic Signatures solution provides the highest number of clinical targets compared to other FDA cleared tests providing ~90%¹ coverage of the most common GI parasite pathogens in the United States

"With the recent FDA enforcement of LDTs, more and more laboratories will be looking for FDA cleared solutions for every day laboratory challenges. Gastrointestinal protozoa testing continues to be one of the biggest challenges in large microbiology laboratories. The 510(k) clearance of the Genetic Signatures EasyScreen™ Gastrointestinal Parasite Detection Kit is significant in that it provides a solution for protozoal testing while obviating the need for laboratories to manage and maintain an LDT within the future framework of the FDA." Prof. Marc Couturier, Ph.D., D(ABMM) Medical Director of Parasitology/Fecal Testing, Infectious Disease Antigen Testing, Medical Director over Emerging Public Health Crises. ARUP Laboratories



Genetic Signatures has invested prior to launch in the United States to accelerate commercialisation post FDA clearance.

 Scale & prepare for launch	 Product availability	 Regulatory	 Reimbursement	 Sales & Marketing
<ul style="list-style-type: none">• Executive team• Direct sales team• Field Services team	<ul style="list-style-type: none">• Manufacturing in Australia• US warehousing and distribution agreements in place• Product available to be shipped• Packaging and labelling agreed with FDA	<ul style="list-style-type: none">• FDA Clearance received• MDSAP• ISO13485	<ul style="list-style-type: none">• Reimbursement coding in place• Customers have existing relationships with payers under the available code• Reimbursement available for private and public providers	<ul style="list-style-type: none">• Launch materials• KOL strategy• Brand positioning• Agencies engaged for offline and online marketing



Nick Samaras
Non Executive Chairman

- Significant experience leading international sales teams
- Former Managing Director of Applied Biosystems (now part of Thermo Fisher)
- Senior executive roles at Perkin Elmer and AMRAD Corporation (now part of CSL)

Michael Aicher
Executive Director

- Currently based in the US with significant experience driving US sales
- Founder of National Genetics Institute
- Led Lab-Corp's esoteric business – generated US\$1bn revenue p.a.

Allison Rossiter
Incoming CEO

- Former MD of Roche Diagnostics Australia
- Extensive experience in global commercialisation of molecular diagnostics technologies
- Previous executive roles based in the US, UK and Canada

Tony Radford
Non Executive Director

- Co-Founder and CEO of Cellestis — acquired by Qiagen for c.US\$400m
- Significant diagnostic sales experience
- Proven track record of executing a sales strategy for medical devices into Europe

Neil Gunn
Non Executive Director

- Currently acting as Interim CEO
- Former President of Roche Sequencing Solution & VP Roche's Molecular Diagnostic business unit
- Responsible for over 120 diagnostic product launches for Roche

Caroline Waldron
Non Executive Director

- ASX governance experience in businesses that intersect heavily with regulation
- C-level leadership of legal, HR, risk and marketing in blue chip businesses
- Cross-border commercial and M&A transaction experience

Stephane Chatonsky
Non Executive Director

- Corporate finance, investment and commercial strategy experience
- Has held executive roles with global organisation such as Lazard, McKinsey & Co and Macquarie Bank



Other growth
initiatives and
catalysts





Fully automated customer driven multi-year instrument development program


“Sample-to-result” Instrument

- Highly automated
- High-throughput (~400 samples/shift)
- Can run multiple products and mixed specimen types in a single run
- Based on proprietary **3base**® technology

Value Proposition

- Further differentiate and automate **3base**® technology
- Provide operational efficiency and reduced labour costs
- Single platform to consolidate multiple tests that are currently conducted on numerous instruments

* Targeted timing may be subject to change.



Images are concepts only





Highly experienced direct sales and support team in place

- Located in the United Kingdom and Germany
- Market transitioning to broader syndromic testing

Channel partnerships in place in select European markets, and recent contracts executed in Israel and the Middle East

- Carefully selected channel partners are deeply experienced and highly connected in their respective markets
- Operating in markets where language and culture requires local representation or where it isn't economic to operate a direct sales force

Distributor Channel Manager in place to support global expansion

- Dedicated resource to provide channel partner training and support to build regional brand equity and sales growth





- **US *EasyScreen*™ Gastrointestinal Parasite Detection Kit**
 - 510(k) clearance now received
 - First revenue anticipated early FY25
 - Targeting to convert pre-qualified customer experience sites to initial customers, post clearance
 - Additional US clinical laboratories targeted for mid FY25
 - Regular commercialisation updates
- **Australian sales of the Respiratory Pathogen Detection Kit to major customers expected to return their full volume**
 - Material revenue uplift following supply authorisation from TGA for updated respiratory kit received in April 2024
- **Increase sales and presence in UK and EMEA markets**
 - Dedicated distribution manager and new distributors to accelerate expansion
- **R&D initiatives for new products**
 - New *EasyScreen*™ detection kits
 - Technology and workflow improvements
 - Development of Next Generation Instrument prototype



Offer Details





Genetic Signatures is conducting a capital raising of up to approximately A\$30.0 million comprising an institutional placement and a fully underwritten pro rata accelerated non-renounceable entitlement offer (together, the 'Offer')

Offer Structure	<ul style="list-style-type: none"> A capital raising of approximately A\$30.0 million which comprises: <ul style="list-style-type: none"> a fully underwritten 1 for 5.82 pro-rata accelerated non-renounceable entitlement offer to eligible shareholders of Genetic Signatures to raise approximately \$24.0 million ('Entitlement Offer'), comprising an Institutional Entitlement Offer to raise approximately \$15.5 million and a Retail Entitlement Offer to raise approximately \$8.5 million; and an institutional placement of approximately \$6.0 million ('Placement') The Entitlement Offer is non-renounceable & entitlements will not be tradeable or otherwise transferable Approximately 40.0 million new fully paid ordinary shares in GSS ('New Shares') to be issued under the Offer, representing approximately 21.5% of existing ordinary shares on issue in Genetic Signatures ('Shares')
Offer Price	<ul style="list-style-type: none"> The Offer will be conducted at a fixed price of A\$0.75 per New Share (Offer Price) which represents: <ul style="list-style-type: none"> A premium of 2.7% to the last close of A\$0.73 on 30 May 2024 A premium of 11.6% to the 5-day VWAP of A\$0.67 up to and including 30 May 2024 A premium of 2.2% to the TERP¹
Institutional Offer	<ul style="list-style-type: none"> The institutional component of the Entitlement Offer and the Placement will be conducted on 4 June 2024 Entitlements not taken up and those of shareholders who are ineligible to participate in the Placement and the Institutional Entitlement Offer will be sold at the Offer Price
Retail Entitlement Offer	<ul style="list-style-type: none"> The retail component of the Entitlement Offer will open on Wednesday, 12 June 2024 and will close at 5.00pm on Monday, 1 July 2024 ('Retail Entitlement Offer') Only eligible shareholders of Genetic Signatures with an address on the Genetic Signatures share register in Australia or New Zealand may participate in the Retail Entitlement Offer
Record Date	<ul style="list-style-type: none"> 7.00pm (Sydney, Australia time) on Thursday, 6 June 2024
Ranking	<ul style="list-style-type: none"> New Shares issued under the Entitlement Offer and Placement will rank pari passu with existing Shares from their date of issue
Underwriters and Joint Lead Managers	<ul style="list-style-type: none"> Bell Potter Securities Ltd and Taylor Collison Ltd

¹TERP is the theoretical price at which Shares should trade after the ex-date for the Entitlement Offer. TERP is calculated by reference to the closing Share price on Thursday, 30 May 2024 of \$0.73 per share, being the last trading day prior to the announcement of the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which Shares trade immediately after the ex-date of the Entitlement Offer will depend on many factors and may not be equal to TERP. TERP includes New Shares to be issued under the Placement.



Funds raised to increase global revenue through instrument and product development

		\$30m raised
Support US Commercialisation	<ul style="list-style-type: none"> Additional sales, field services and marketing resources to support new commercialisation activities in the United States 	\$7.5m
Expansion of manufacturing to the US	<ul style="list-style-type: none"> New site in the United States to dispense product for the US Market 	\$2.0m
Funding for new customer installations	<ul style="list-style-type: none"> Customer evaluations, FOC Kits, support Instrumentation held at US customer sites. High expected ROI – will recoup a multiple of initial outlay via long-term consumable revenue 	\$4.5m
Next Generation Instrument development and new product development	<ul style="list-style-type: none"> Next Generation Instrument development – future proof GSS in global MDx market New product development - increase pipeline of new products to expand the portfolio 	\$8.5m
	<ul style="list-style-type: none"> Working capital and capital raising costs 	\$7.5m
	Total	\$30m



Key events	Sydney, Australia time
Back-to-back trading halt	Friday, 31 May 2024
Announcement of the Offer	Tuesday, 4 June 2024
Institutional Entitlement Offer Opens	Tuesday, 4 June 2024
Announcement of results of Institutional Entitlement Offer and Placement	Thursday, 6 June 2024
Trading halt lifted	Thursday, 6 June 2024
Record Date for Entitlement Offer	7:00pm AEST, Thursday, 6 June 2024
Settlement of Placement and Institutional Entitlement Offer	Wednesday, 12 June 2024
Retail Entitlement Offer opens and Retail Offer Booklet despatched	Wednesday, 12 June 2024
Issue of New Shares under the Placement and Institutional Entitlement Offer	Thursday, 13 June 2024
Retail Entitlement Offer closes	5:00pm AEST, Monday, 1 July 2024
Results of the Retail Entitlement Offer announced	Thursday, 4 July 2024
Settlement of Retail Entitlement Offer	Friday, 5 July 2024
Allotment of Retail Entitlement Offer Securities	Monday, 8 July 2024
Commencement of trading of New Shares issued under the Retail Entitlement Offer	Tuesday, 9 July 2024

1. Dates / times are indicative and subject to change.

Appendix





Financial information

Share price (30-May-24)	A\$0.73
Shares on issue	186.5m

Market capitalisation **A\$136.1m**

Cash (31-Mar-24) A\$20.4m

Debt (31-Mar-24) Nil

Enterprise value **A\$115.7m**

Top shareholders %

Asia Union (Chris Abbott private investment)	23.5%
Perennial Value Management	12.4%
Fidelity International	9.7%
Directors & management	2.1%





Genetic Signatures develops and markets differentiated molecular diagnostic testing kits for syndromic testing for infectious diseases used by clinical laboratories

Infectious diseases are a leading cause of death


- This is often preventable through more accurate diagnosis and timely treatment

Molecular PCR diagnostic tests target unique genetic signatures (DNA)

- These DNA sequences are screened in patient samples and flagged if a pathogen is detected
- Simultaneous screening for all pathogens that can cause the same symptoms is known as “syndromic testing”
- This method is highly accurate and can test for a wide range of infectious diseases including respiratory, enteric (intestinal illness) and sexual health

Genetic Signatures' unique 3base® technology simplifies syndromic testing for infectious diseases

- **Standardised workflow** – Multiple sample types and organisms treated with same workflow
 - Single test to screen for multiple infections which supports faster diagnosis and treatment
 - Less time evaluating samples and more testing results per patient specimen



3base[®] converts the original 4-base microbial genome to 3-base simplifying the overall genetic sequence

By simplifying the sequence **3base[®]** allows laboratories to test a wider array of patient infections and can detect multiple pathogen strains within a single test

* Human Papilloma virus sequences

Able to detect pathogen variants (i.e. strains or subtypes) – more tolerant of mutations

3base[®] conversion does not impact sensitivity or specificity and does not require any extra user steps





1. KEY RISKS

Investors should be aware that an investment in Genetic Signatures involves risks. The key risks identified by Genetic Signatures are set out in the "Key Risks" section of the Investor Presentation (below), but these are not an exhaustive list of the risks associated with an investment in the Shares. You should consider these risks carefully in light of your personal circumstances, including financial and taxation issues, before making an investment decision in connection with the Entitlement Offer. Genetic Signatures' financial position and performance, its dividends and the market price of Genetic Signatures' shares may be adversely affected, sometimes materially, by a number of risk factors. Holders of Genetic Signatures shares ('Genetic Signatures Shareholders') should accordingly be aware that an investment in Genetic Signatures carries a number of risks, some of which are specific to Genetic Signatures and some of which are general risks that relate to the industries in which Genetic Signatures operates or to listed securities generally. These risks mean that the price and value of Genetic Signatures shares may rise or fall over any given period. Some of these risks are beyond Genetic Signatures' control.

Genetic Signatures Shareholders should be aware of the following risks (which are some, but not necessarily all of the risks) which may affect the future operating and financial performance of Genetic Signatures and the value of Genetic Signatures shares. Additional risk and uncertainties that Genetic Signatures is unaware of, or that it currently considers to be immaterial, may also become important factors that adversely affect Genetic Signatures' operating and financial performance. Before investing in Genetic Signatures shares, you should consider whether this investment is suitable for you. Potential investors should also consider publicly available information on Genetic Signatures (such as that available on the website of Genetic Signatures and ASX) and carefully consider their personal circumstances and consult their stockbroker, solicitor, accountant or other professional advisor to ensure they understand fully the terms of the Entitlement Offer and the inherent risk before making an investment decision.

REGULATORY AND LITIGATION RISK

Genetic Signatures is subject to regulatory and licensing requirements, and its business is sensitive to regulatory changes. Obtaining and maintaining approvals from regulatory bodies or other third parties can involve significant time and expense, and delays in obtaining approvals or changes to laws and regulations may adversely impact Genetic Signatures' operations. Genetic Signatures may also be subject to litigation in the future and there can be no assurance that the outcome of legal proceedings from time to time will not have an adverse effect on Genetic Signatures' businesses, financial performance, financial condition or prospects.

INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS

If a third party accuses Genetic Signatures of infringing its intellectual property rights or if a third party commences litigation against Genetic Signatures for the infringement of patents or other intellectual property rights, Genetic Signatures may incur significant costs in defending such action, whether or not it ultimately prevails. Typically, intellectual property litigation is expensive. Costs that Genetic Signatures incurs in defending third party infringement actions would also include diversion of management's and technical personnel's time. In addition, parties making claims against Genetic Signatures may be able to obtain injunctive or other equitable relief that could prevent Genetic Signatures from further developing discoveries or commercialising its products. In the event of a successful claim of infringement against Genetic Signatures, it may be required to pay damages and obtain one or more licenses from the prevailing third party. If it is not able to obtain these licenses at a reasonable cost, if at all, it could encounter delays in product introductions and loss of substantial resources while it attempts to develop alternative products.

RESTRAINTS ON INNOVATION

The emergence of technical developments providing an alternative to Genetic Signatures' product offerings could result in the acquisition by competitors to Genetic Signatures of intellectual property rights (e.g. patents) which may prevent Genetic Signatures from developing or commercialising its own discoveries in countries in which the third party has those intellectual property rights. Such third-party intellectual property rights could impact the market share that Genetic Signatures is able to acquire in the affected countries.



COUNTRY/REGION SPECIFIC RISKS IN NEW AND/OR UNFAMILIAR MARKETS

Genetic Signatures has operations in a number of overseas jurisdictions and is exposed to a range of different legal and regulatory regimes, including in new jurisdictions in which Genetic Signatures is expanding its operations. As Genetic Signatures expands its presence in new international jurisdictions, Genetic Signatures is subject to the risks associated with doing business in regions that may have political, legal and economic instability or less sophisticated legal and regulatory systems and frameworks including, (i) unexpected changes in, or inconsistent application or enforcement of applicable foreign laws and regulatory requirements;

(ii) less sophisticated technology standards;

(iii) difficulties engaging local resources; and

(iv) potential for political upheaval or civil unrest.

As Genetic Signatures enters newer and less familiar regions, there is a risk that it fails to understand the law, regulations and business customs of these regions. This gives rise to risks relating to labour practices, foreign ownership restrictions, tax regulation, difficulty in enforcing contracts, changes to or uncertainty in the relevant legal and regulatory regimes and other issues in foreign jurisdictions in which Genetic Signatures may operate. This could interrupt or adversely affect parts of Genetic Signatures' business and may have an adverse effect on Genetic Signatures' business operations and financial performance.

OPERATIONAL RISK

Operational risk is the risk of loss resulting from inadequate or failed internal processes, people or systems (including information security systems), or from external events. Genetic Signatures is exposed to a variety of risks including those arising from process error, fraud, technology failure, security and physical protection, staff skills, workplace safety, compliance, business continuity and crisis management.

EARLY-STAGE RISK

Genetic Signatures is subject to risks common to early-stage companies, including increasing market share and brand recognition, developing its product pipeline, competition risk and satisfying regulatory requirements imposed on Genetic Signatures and its products. An investment in Genetic Signatures is speculative, and risks associated with investments in early-stage companies, such as Genetic Signatures, are generally considered high. If Genetic Signatures is not successful in addressing such risks, the Company's business prospects and financial performance may be materially and adversely affected and the Company may never become profitable.

UNCERTAINTY OF FUTURE REVENUE AND PROFITABILITY

Future sales of products and Genetic Signatures' future profitability are contingent on, amongst other things, Genetic Signatures' ability secure contracts with customers by their direct sales force, enter into appropriate distribution and partner arrangements, being able to maintain anticipated prices for products being acquired as well as certainty of supply, being able to set favourable prices for products being sold, market demand for products being sold, general economic conditions, the results of further research and clinical trials in relation to molecular diagnostics products. Consequently, Genetic Signatures cannot provide any guarantee that future sales estimates will be achieved. Even if future sales estimates are achieved, they may not result in Genetic Signatures being profitable.



LOSS OF ADOPTION BY CUSTOMERS

Genetic Signatures is reliant on pathology laboratories purchasing its products. Healthcare practitioners play a significant role in influencing the types of tests and products used by patients. To achieve commercial success, Genetic Signatures is reliant on pathology laboratories accepting the scientific validity and usefulness of its current and planned testing products. Pathology laboratories may be slow to adopt and recommend Genetic Signatures products to their patients for a number of reasons. While Genetic Signatures has strong relationships with various laboratories, this does not guarantee sufficient adoption of Genetic Signatures' products domestically and in international markets necessary to achieve profitability.

LOSS OF KEY MANAGEMENT PERSONNEL

The successful operation of Genetic Signatures in part relies on Genetic Signatures' ability to attract and retain experienced and high performing key management personnel, in particular those with relevant scientific expertise. The loss of any key members of management or other personnel, or the inability to attract additional skilled individuals to key management roles, may adversely affect Genetic Signatures' ability to develop and implement its business strategies.

OWNERSHIP AND PROTECTION OF INTELLECTUAL PROPERTY

The business of Genetic Signatures depends on its ability to commercially exploit its intellectual property. Genetic Signatures relies on laws relating to patents, trade secret, copyright and trade marks to assist in protecting its proprietary rights. There is a risk that unauthorised use or copying of the secure documentation (electronic laboratory books), business data or intellectual property will occur. There is a risk that Genetic Signatures may be unable to detect the unauthorised use of its intellectual property rights in all instances. Any breaches of Genetic Signatures' intellectual property may result in the need to commence legal action, which could be costly and time-consuming. A failure or inability to protect Genetic Signatures' intellectual property rights could have an adverse impact on operating and financial performance.

FAILURE TO REALISE BENEFITS FROM PRODUCT RESEARCH AND DEVELOPMENT

The development and commercialisation of the Company's products is expensive and often involves an extended period of time to achieve return on investment. An important aspect of Genetic Signatures' business is to continually invest in innovation and product development opportunities. Genetic Signatures may not realise benefits from these investments for several years, or may not realise benefits at all in some cases. Genetic Signatures makes assumptions about the expected future benefits generated by investment in product research and development and the expected timeframe in which the benefits will be realised. These assumptions are subject to change and involve both known risks and risks that are beyond Genetic Signatures' control. Any change to the assumptions Genetic Signatures has made about certain product development may have an adverse impact on Genetic Signatures' ability to realise benefit from investment in the development of the products.

MARKET ACCEPTANCE AND COMPETITOR RISK

Market acceptance depends on numerous factors, including convincing potential consumers and agents of the attractiveness of Genetic Signatures' products and the ability to manufacture those products to a sufficient quality and quantity to meet commercial demand at an acceptable cost. There is a risk that Genetic Signatures' products may not gain widespread market acceptance, and this may adversely affect the financial performance of Genetic Signatures. There is also a risk that Genetic Signatures may not be able to effectively compete with other participants in this market.



GENERAL REGULATORY RISKS

The Company operates and intends to operate in regulated industries (including but not limited to medical devices, diagnostics and therapeutics) in Australia and internationally. Given Genetic Signatures' international expansion plans, securing and maintaining the necessary regulatory approvals for its products and services in all markets in which they are sold and offered respectively will be critical to the performance of Genetic Signatures. There is a risk that regulatory approvals for Genetic Signatures' products and services will fail to be obtained or maintained in some or all of the markets in which they are sold and offered respectively. This may have an impact on the financial performance of Genetic Signatures and expose it to potential liabilities or third-party claims. Further, the failure by Genetic Signatures to comply with the laws and regulations in the jurisdictions in which it operates could result in the loss of access to those and other markets. In addition, compliance with government regulations may also subject Genetic Signatures to additional fees and costs. Further, changes to these laws and regulations (including interpretation and enforcement), or the failure by Genetic Signatures to remain current with those changes, could adversely affect Genetic Signatures' business and financial performance.

SUFFICIENCY OF FUNDING AND ADDITIONAL REQUIREMENTS FOR CAPITAL

Genetic Signatures has provided an indication of how it intends to apply its existing funds, including funds raised under the Offer. There is a risk that the costs of operations may be higher than anticipated or increase as a result of unforeseen circumstances (which may include circumstances related to other key risk factors). Genetic Signatures may also be required to raise additional equity or debt capital in the future. There is no assurance that Genetic Signatures will be able to raise that capital when it is required or that it will be able to raise that capital on such terms satisfactory or favourable to the Company. If Genetic Signatures is unsuccessful in obtaining funds when required, it may need to delay or cease its research and development, commercialisation, manufacturing activities, or other components of its business. In the event of insufficient capital, Genetic Signatures may also have to license or sell its technologies on unfavourable terms, or scale down or cease operations. No assurance can be given that future funding will be available to the Company, on any particular terms, or at all.

UNDERWRITING RISK

The Company has entered into the Underwriting Agreement with Bell Potter Securities Limited and Taylor Collison Limited (**Underwriters**). Pursuant to the Underwriting Agreement, the Company appointed the Underwriters to fully underwrite the Entitlement Offer. The material terms of the Underwriting Agreement are set out in this presentation. If certain conditions are not satisfied or certain events occur, the Underwriters may terminate the Underwriting Agreement. There is always a risk the Underwriting Agreement is terminated before settlement of the Retail Entitlement Offer. If the Underwriting Agreement is terminated and the Offer does not proceed or does not raise the funds required for the Company to meet its stated objectives the Company would be required to find alternative financing or curtail its activities. In those circumstances, there is no guarantee that alternative funding could be sourced in the time required or at all or that the Company would be able to successfully negotiate the terms of any debt or equity funding arrangements in those circumstances.

FAILURE OF RISK MANAGEMENT STRATEGIES

Genetic Signatures has implemented risk management strategies and internal controls involving processes and procedures intended to manage business risks as they arise. However, there are inherent limitations with any risk management framework as risks may arise that Genetic Signatures has not anticipated or identified. Additionally, if any of Genetic Signatures' risk management processes and procedures prove ineffective or inadequate or are otherwise not appropriately implemented, Genetic Signatures could suffer unexpected losses and reputational damage which could adversely impact Genetic Signatures' financial performance, financial position and prospects.

CHANGES TO ACCOUNTING POLICIES AND/OR METHODS IN WHICH THEY ARE APPLIED MAY ADVERSELY AFFECT GENETIC SIGNATURES' BUSINESS, OPERATIONS AND FINANCIAL CONDITION

The accounting policies and methods that Genetic Signatures applies are fundamental to how it records and reports its financial position and results of operations. Genetic Signatures must exercise judgment in selecting and applying many of these accounting policies and methods as well as estimates and assumptions applied so that they not only comply with generally accepted accounting principles, but they also reflect the most appropriate manner in which to record and report on the financial position and results of operations. In recording and reporting its financial position there is a risk that these accounting policies may be applied inaccurately, and/or incorrect assumptions or judgments made, resulting in a misstatement of financial position and results of operations. This may lead to an adverse impact on Genetic Signatures' financial performance, financial position and prospects.



INSURANCE RISK

Genetic Signatures maintains a level of insurance coverage. If Genetic Signatures' third-party providers fail to perform their obligations and/or its third-party insurance cover is insufficient for a particular matter or group or related matters, or there is an adverse event in respect of the third-party insurer or Underwriters, the net loss to Genetic Signatures could adversely impact Genetic Signatures' financial performance, financial position and prospects. Future changes to insurance market conditions may also result in material or significant increases in the cost of obtaining insurance, and/or impact the ability for Genetic Signatures to obtain insurance coverage:

- (i) in respect of certain risks;
- (ii) to the extent to which it had previously obtained; or
- (iii) to a level it considers prudent for the scope and scale of its activities.

STRATEGIC RISK

A failure to execute Genetic Signatures' strategic objectives may result in a failure to achieve anticipated benefits and ultimately adversely impact Genetic Signatures' operations, financial performance, financial position and prospects.

RELIANCE ON EXTERNAL PARTIES

Genetic Signatures' operations depend on performance by a number of external parties under contractual arrangements with Genetic Signatures. Non-performance of contractual obligations and poor operational performance of external parties may have an adverse effect on Genetic Signatures' business and financial performance.

REPUTATION RISK

The reputation and brand of Genetic Signatures and its individual products are important in attracting potential customers. Any reputational damage or negative publicity around Genetic Signatures or its products could adversely impact on Genetic Signatures' business.



2. OFFER AND GENERAL RISKS

MARKET PRICE OF ORDINARY SHARES WILL FLUCTUATE

Ordinary shares trade on ASX. The market price of ordinary shares on ASX may fluctuate due to various factors, including:

- Australian and international general economic conditions (including inflation rates, the level of economic activity, interest rates and currency exchange rates), changes in government policy, changes in regulatory policy, the expressed views of regulators, investor sentiment and general market movements, which may or may not have an impact on Genetic Signatures' actual operating performance;
- operating results that vary from expectations of securities analysts and investors;
- changes in expectations as to Genetic Signatures' future financial performance, including financial estimates by securities analysts and investors;
- changes in market valuations of competitors;
- changes in dividends paid to shareholders, Genetic Signatures' dividend payout policy or Genetic Signatures' ability to frank dividends;
- announcement of the results of tenders, entry into or cessation of contracts, acquisitions, strategic partnerships, joint ventures or capital commitments by Genetic Signatures or its competitors;
- changes in the market price of ordinary shares and / or other securities issued by Genetic Signatures or by other issuers, or changes in the supply of equity securities or capital securities issued by Genetic Signatures or by other issuers;
- changes in institutional or shareholder (including director) portfolio management or shareholding strategies;
- changes in laws, regulations and regulatory policy;
- Genetic Signatures' failure to comply with law, regulations or regulatory policy; and
- other major Australian and international events such as hostilities and tensions, and acts of terrorism.

It is possible that the price of ordinary shares will trade at a market price below the Entitlement Offer price as a result of these and other factors. It is also possible that new risks might emerge as a result of Australian or global markets experiencing extreme stress or existing risks may manifest themselves in ways that are not currently foreseeable. There have been in recent months, and may be in the future, significant fluctuations and volatility in the prices of shares.

DILUTION

If Genetic Signatures Shareholders do not participate in the Entitlement Offer, then their percentage shareholding in Genetic Signatures will be diluted and they will not be exposed to future increases or decreases in Genetic Signatures' share price in respect of those New Shares that would have been issued to them had they participated in the Placement (if eligible) or the Entitlement Offer. Similarly, Genetic Signatures Shareholders who are ineligible, unable to, or do not participate in the Placement or Entitlement Offer will have their percentage security holding in Genetic Signatures diluted.



LIQUIDITY RISK

Genetic Signatures Shareholders who wish to sell their ordinary shares may be unable to do so at an acceptable price, or at all, if insufficient liquidity exists in the market for ordinary shares. Genetic Signatures does not guarantee the market price or liquidity of ordinary shares and there is a risk that you may lose some of the money you invested.

DIVIDENDS MAY FLUCTUATE OR MAY NOT BE PAID

Dividends are discretionary and do not accrue. The rate of dividends may fluctuate or Genetic Signatures may not pay dividends at all. There is a risk that dividends may become less attractive compared to returns on comparable securities or investments. None of Genetic Signatures, Genetic Signatures' directors or any other person guarantees any particular rate of return on ordinary shares.

TAXATION

Any change to the current rate of company income tax or tax law in jurisdictions where Genetic Signatures operates may impact on Genetic Signatures Shareholder returns. Any changes to the current rates of income tax or tax law applying to Genetic Signatures Shareholders, whether they are individuals, trusts or companies may similarly impact on Genetic Signatures Shareholder returns. Current income tax laws may result in changes both beneficial and adverse to Genetic Signatures Shareholder returns to tax attributes (including but not limited to future deductions, tax losses, and available tax credits and offsets).

SHAREHOLDERS ARE SUBORDINATED AND UNSECURED INVESTORS

In a winding up of Genetic Signatures, Genetic Signatures Shareholders' claims will rank after the claims of creditors preferred by law, secured creditors and general creditors. Genetic Signatures Shareholders' claims will rank equally with claims of holders of all other ordinary shares. If Genetic Signatures were to be wound up and, after the claims of creditors preferred by law, secured creditors, general creditors and holders of subordinated instruments (if any) are satisfied, there are insufficient assets remaining, you may lose some or all of the money you invested in ordinary shares.

FUTURE ISSUES OF DEBT OR OTHER SECURITIES BY GENETIC SIGNATURES

Genetic Signatures may, at its absolute discretion, issue additional securities in the future that may rank ahead of, equally with or behind ordinary shares, whether or not secured. Any issue or conversion of securities may dilute the relative value of existing ordinary shares and affect your ability to recover any value in a winding up. An investment in ordinary shares confers no right to restrict Genetic Signatures from raising more debt or issuing other securities (subject to restrictions imposed under the ASX Listing Rules), to require Genetic Signatures to refrain from certain business changes, or to require Genetic Signatures to operate within potential certain ratio limits.

An investment in ordinary shares carries no right to participate in any future issue of securities (whether equity, hybrid, debt or otherwise), other than future pro rata issues if the Genetic Signatures Shareholder is eligible to participate in the pro rata issue under relevant laws. No prediction can be made as to the effect, if any, such future issues of debt or other issues of securities may have on the market price or liquidity of ordinary shares.

OTHER EXTERNAL EVENTS

Acts of terrorism, an outbreak of international hostilities, labour strikes, civil wars or fires, floods, earthquakes, cyclones and other natural disasters (including where the frequency and severity of such events increase as a result of the effects of climate change), and outbreaks of disease and biosecurity threats such as COVID-19 may cause an adverse change in investor sentiment with respect to Genetic Signatures specifically or the share market more generally, which could have a negative impact on the value of an investment in ordinary shares.



International Offer Restrictions

This Presentation does not constitute an offer of new ordinary shares ('New Shares') of the Company in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

New Zealand

This Presentation has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the 'FMC Act').

The New Shares are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.

Other than in the Entitlement Offer, the New Shares may only be offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Hong Kong

WARNING: This Presentation has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this Presentation may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance). No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities. The contents of this Presentation have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this Presentation, you should obtain independent professional advice.

Singapore

This Presentation and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this Presentation and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA. This Presentation has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this Presentation immediately. You may not forward or circulate this Presentation to any other person in Singapore. Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

United States

This Presentation has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this Presentation have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Summary of Underwriting Arrangements



The Company has entered into an underwriting agreement ('Underwriting Agreement') with Bell Potter Securities Limited and Taylor Collison Limited (each a 'Joint Lead Manager', and together the 'Joint Lead Managers') pursuant to which the Joint Lead Managers have agreed to act as the joint lead managers to the Offer and underwriters of the Entitlement Offer in accordance with the terms and conditions of the Underwriting Agreement.

Key terms of the Underwriting Agreement

The following fees are payable to the Joint Lead Managers under the Underwriting Agreement:

- a management fee of 3% and a selling fee of 3% of the gross proceeds of the Placement; and
- a management fee of 3% and an underwriting fee of 3% of the gross proceeds of the Entitlement Offer, (together, the 'Fees'). The Fees are payable 50% to each Joint Lead Manager.

Each Joint Lead Manager's obligations under the Underwriting Agreement, including to underwrite and manage the Entitlement Offer, are conditional on certain matters, including (but not limited to) certain Offer Materials (defined below) being released within the required timeframes and certain other diligence-related deliverables being provided within the required timeframes. A reference to 'Group' in this summary of the Underwriting Agreement means the Company and each of its subsidiaries.

The Company has provided customary representations and warranties relating to the Offer and the Company's operations, and various undertakings in relation to the Company and conduct of the Offer, in favour of the Joint Lead Managers. The Company has indemnified the Joint Lead Managers and their affiliates from any losses incurred from the performance of the Joint Lead Managers' obligations under the Underwriting Agreement, on customary terms.

If certain conditions are not satisfied or certain events occur, the Joint Lead Managers may terminate the Underwriting Agreement. Termination of the Underwriting Agreement by the Joint Lead Managers may have a material adverse impact on the total amount of proceeds that could be raised under the Offer, which in turn would have a material adverse impact on the Company's financial position.

The events which may trigger termination of the Underwriting Agreement include (but are not limited to) the following:

- **(Misleading disclosure)** a statement contained in the ASX announcement, cleansing statements, retail offer booklet, confirmation Letters, all correspondence delivered to securityholders or excluded securityholders in respect of the Offer and any public information (**Offer Materials**) is or becomes misleading or deceptive or likely to mislead or deceive or a matter required to be included is omitted from the Offer Materials;
- ***(Information)** the Due Diligence Committee Report or any information supplied by or on behalf of the Company to the Joint Lead Managers for the purposes of the due diligence investigations, the Offer Materials, or the Offer, is false, misleading or deceptive or likely to mislead or deceive (including by omission);
- **(Entitlement Offer Cleansing Statement)** a notice given to ASX by the Company under section 708AA(2)(f) of the Corporations Act in respect of the Entitlement Offer (**Entitlement Offer Cleansing Statement**) is defective, or a notice is given to the ASX under section 708AA(10) of the Corporations Act to correct an Entitlement Offer Cleansing Statement (other than as a result of a new circumstance arising);
- **(Placement Cleansing Statement)** a notice given to ASX by the Company under section 708A(5)(e) of the Corporations Act in respect of the Placement (**Placement Cleansing Statement**) is defective, or a notice is given to the ASX under section 708A(9) of the Corporations Act to correct an Entitlement Offer Cleansing Statement (other than as a result of a new circumstance arising);
- **(New circumstance)** an obligation arises on the Company to give ASX a notice in accordance with section 708AA(12) of the Corporations Act or a new circumstance arises or becomes known which, if known at the time of issue of any Offer Materials would have been required to be included in those Offer Materials;
- ***(Material adverse change)** any adverse change, or development (including but not limited to any regulatory change) or event involving a change, in the condition, financial or otherwise, or in the assets, liabilities, earnings, business, operations, management, profits, losses or prospects of the Company, or the Group other than as disclosed by the Company to the ASX before the date of the Underwriting Agreement or in the Offer Materials;
- **(Market fall)** at any time the S&P/ASX 200 Index closes at a level that is 10% below the level of the S&P/ASX 200 Index as at the close of trading on the business day prior to the date of the Underwriting Agreement;
- ***(Change of law)** there is introduced or there is a public announcement of a proposal to introduce, into the Parliament of Australia or any State of Australia a new law, or the Reserve Bank of Australia, or any Commonwealth or State authority, adopts or announces a proposal to adopt a new policy (other than a law or policy which has been announced before the date of this document), any of which does or in the reasonable opinion of the Joint Lead Managers is likely to prohibit or adversely affect or regulate the Offer, capital issues or stock markets or the Joint Lead Managers' ability to promote or market the Offer or enforce contracts to issue or allot the New Shares under the Offer, or adversely affect the taxation treatment of the New Shares;



Key terms of the Underwriting Agreement (continued)

- **(Future matters)** any estimate or expression of opinion, belief, expectation or intention, or statement relating to future matters (including any forecast or prospective financial statements, information or data or the assumptions or sensitivity in relation thereto) in the Offer Materials or any Public Information is not truly and honestly held or there are no reasonable grounds for making any such statement or any other announced forecast or expectation becomes incapable of being met;
- **(Unable to proceed)** the Company is or will be prevented from conducting or completing the Offer (including granting the Entitlements or issuing New Shares) by or in accordance with the Listing Rules, ASIC, ASX, any applicable laws or an order of a court of competent jurisdiction, or otherwise are or will become unable or unwilling to do any of these things or a third party applies to a court of competent jurisdiction seeking orders to prevent, or which will have the effect of preventing any of these things;
- **(Force majeure)** there is an event or occurrence, including any statute, order, rule, regulation, directive or request (including one compliance with which is in accordance with the general practice of persons to whom the directive or request is addressed) of any Government Agency which makes it illegal for the Joint Lead Managers to satisfy an obligation under the Underwriting Agreement or to market, promote or settle the Offer;
- **(Listing):**
 - the Company ceases to be admitted to the official list of ASX or its securities (or interests in them) cease trading or are suspended from official quotation or cease to be quoted on the ASX; or
 - ASX makes any official statement to any person, or indicates to the Company or the Joint Lead Managers that it will not grant permission for the official quotation of the New Shares, or permission is granted before the date of issue of the New Shares, but the approval is subsequently withdrawn, qualified or withheld;
- **(Applications)** an application is made by ASIC for an order under Part 9.5 of the Corporations Act in relation to the Offer Materials or the Offer or ASIC commences, or gives notice of an intention to hold, any investigation or hearing in relation to the Offer or any of the Offer Materials or prosecutes or commences proceedings against or gives notice of an intention to prosecute or commence proceedings against the Company;
- **(No misleading or deceptive conduct)** the Company engages in conduct that is misleading or deceptive or which is likely to mislead or deceive in connection with the making of the Offer, in each case in any material respect;
- **(Withdrawal)** the Company withdraws or indicates that it does not intend to proceed with the Offer or any part of the Offer or withdraws a document forming part of the Offer Materials;
- ***(Market disruption)** either of the following occurs:
 - a general moratorium on commercial banking activities in Australia, the United States of America, Singapore, Hong Kong or the United Kingdom is declared by the relevant central banking authority in any of those countries; or
 - trading in all securities quoted or listed on ASX, the London Stock Exchange, the Hong Kong Stock Exchange or the New York Stock Exchange is suspended or limited in a material respect for more than one day on which that exchange is open for trading;
- ***(Hostilities)** any of the following occurs:
 - there is an outbreak of hostilities not presently existing or a major escalation in existing hostilities occurs (in each case, whether or not a war or a national emergency has been declared);
 - a declaration is made of a national emergency or war, excluding any war or hostilities presently existing as at the date of this document; or
 - a major terrorist act is perpetrated;involving any one or more of Australia, New Zealand, the United States of America, the United Kingdom, any member state of the European Union, any member state of the North Atlantic Treaty Organization, the People's Republic of China, Hong Kong, South Korea, Japan, Singapore, Russia, Ukraine, Israel, Palestine or Iran; or
 - a pandemic, epidemic or large-scale outbreak of a disease (including without limitation SARS, swine or avian flu, H5N1, H7N9, COVID-19 or a related or mutated form of these) not presently existing occurs or in respect of which there is a major escalation, including an escalation resulting in a material shut-down of business around the world;
- ***(Representations and warranties)** a representation and warranty contained in the Underwriting Agreement on the part of the Company is untrue or incorrect when given or taken to be given or becomes untrue or incorrect;
- ***(Certificate)** any Certificate which is required to be furnished by the Company under the Underwriting Agreement is untrue, incorrect or misleading;
- **(Certificate not furnished)** any Certificate which is required to be furnished by the Company under the Underwriting Agreement is not furnished when required;
- **(Delay)** an event specified in the timetable contained in the Underwriting Agreement is delayed by the Company other than with the consent of the Joint Lead Managers;



Key terms of the Underwriting Agreement (continued)

- ***(Political or economic conditions)** the occurrence of any adverse change or disruption to financial, political or economic conditions, currency exchange rates or controls or financial markets in Australia, New Zealand, the United States of America, the United Kingdom, the People's Republic of China, Hong Kong or Singapore that does not already exist or has not already been announced as at the date of the Underwriting Agreement;
- **(Unauthorised change)** the Company or a member of the Group:
 - disposes, or agrees to dispose, of the whole, or a substantial part, of its business or property other than as contemplated in the Offer Materials;
 - ceases or threatens to cease to carry on business; or
 - alters its capital structure, other than as contemplated in the Offer Materials;
- **(Constitution)** the Company or a member of the Group amends its constitution or other constituent document of a member of the Group or announces a proposal to amend its constitution other than an amendment disclosed to the Joint Lead Managers prior to the date of this document;
- ***(Breach)** the Company is in breach of any terms and conditions of this agreement (including for the avoidance of doubt, undertakings) or fails to perform or observe any of its obligations under the Underwriting Agreement;
- ***(Compliance)**:
 - a contravention by the Company or any member of the Group of the Corporations Act, the Constitution (or equivalent applicable documents), the Listing Rules, any applicable laws, or a requirement, order or request made by or on behalf of the ASIC, ASX or any other Government Agency or any agreement entered into by it; or
 - any Offer Materials or any aspect of the Offer does not comply with the Corporations Act, the Listing Rules, the ASX Waivers or any other applicable law or regulation;
- **(Change in directors or management)** a change to the chief executive officer, chief financial officer, chief operating officer or the board of directors of the Company occurs, or any such changes are announced, other than as contemplated in the Offer Materials;
- **(Legal proceedings and offence by Directors)** any of the following occurs:
 - legal proceedings are commenced against the Company or any member of the Group;
 - the Company, a director or senior member of management of the Company engages in any fraudulent conduct or activity, or is charged with an indictable offence, whether or not in connection with the Offer;
 - any Government Agency commences any public proceedings against the Company or any director in their capacity as a director of the Company, or announces that it intends to take such action; or
 - any director of the Company is disqualified from managing a corporation under Part 2D.6 of the Corporations Act;
- ***(Public statements)**: a statement in any of the Public Information is or becomes misleading or deceptive or likely to mislead or deceive;
- **(Encumbrance)** other than in the ordinary course of business a person Encumbers or agrees to Encumber, the whole or a substantial part of the business or property of the Company or the Group;
- **(ASX Waivers or ASIC Modifications)** ASX withdraws, revokes or amends any ASX Waivers or ASIC Modifications;
- **(Trading Halt)** the Trading Halt ends before the expiry of the relevant period referred to in the timetable without the prior written consent of the Joint Lead Managers;
- **(Insolvency)** an Insolvency Event occurs in relation to a Group member or there is an act which has occurred or any omission made which would result in an Insolvency Event occurring in respect of any Group member; and
- **(Prescribed occurrence)** an event specified in sections 652C(1) or (2) of the Corporations Act occurs, in relation to the Company or any other Group member.

A Joint Lead Manager may, by notice given to the Issuer and the other Joint Lead Manager, and without cost or liability to that Joint Lead Manager, immediately terminate the Underwriting Agreement if any one or more of the termination events occurs and:

- (Unqualified) that termination event is not marked with an “**”; or
- (Qualified) that termination event is marked with an “**” and, in the reasonable opinion of the Joint Lead Managers:
 - the event has had or is likely to have a material adverse effect on the financial condition, financial position or financial prospects of the Company, the Group, or the market price of the New Shares; or
 - the event has had or is likely to have a material adverse effect on the success or outcome of the Offer; or
 - the Joint Lead Managers will or are likely to contravene, be involved in a contravention of, or incur a liability under the Corporations Act or any other applicable law as a result of the event.



Contact Us

Dr Neil Gunn

Interim Chief Executive Officer

E: neil.gunn@geneticsignatures.com

P: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial & Operating Officer &
Company Secretary

E: karl.pechmann@geneticsignatures.com

Visit us

www.geneticsignatures.com

Follow us



Not for distribution or release in the United States or to U.S. persons

ASX Announcement

6 June 2024

GENETIC SIGNATURES SUCCESSFULLY COMPLETES INSTITUTIONAL ENTITLEMENT OFFER AND PLACEMENT

Genetic Signatures Limited ACN 095 913 205 (GSS, Genetic Signatures or the Company) is pleased to announce the successful completion of the bookbuild for the institutional placement (**Placement**) and the institutional component (**Institutional Entitlement Offer**) of its 1 for 5.82 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer** and, together with the Placement, the **Offer**) of new fully paid ordinary shares in Genetic Signatures (**New Shares**), details of which were announced to the ASX on Tuesday, 4 June 2024.

The Placement and Institutional Entitlement Offer closed on Wednesday, 5 June 2024 (together, the **Institutional Offer**).

The Institutional Offer will raise gross proceeds of approximately A\$21.5 million (before costs) at an offer price of A\$0.75 per New Share, consisting of approximately A\$6.0 million under the Placement and approximately A\$15.5 million under the Institutional Entitlement Offer. The Institutional Offer attracted strong demand from existing institutional shareholders of the Company, and also introduced several new institutional investors to the Genetic Signatures register.

Funds raised under the Offer will be applied towards supporting the US commercialisation of the Enteric Parasite product in the US, including new customer installations and establishment of manufacturing capability in the US. In addition, proceeds will be used to fund the next generation instrument development, new product development and general working capital.

"We appreciate the strong support we have seen from both new and existing shareholders in this capital raise," said Dr Nick Samaras, Non-Executive Chairman of Genetic Signatures. "The Company is at a pivotal time in its history to commercialise the Enteric Parasite test in the US which will greatly improve patient diagnosis and treatment outcomes. The development of our high-throughput, sample-to-answer instrument will progress and promises to be a game-changer for the high-volume user sites we will be targeting in the US market. The proceeds from this raise provides the Company with the balance sheet it requires to fully realise the potential of these exciting growth opportunities."

No shareholder approval is required in connection with the issue of New Shares under the Placement, as the Placement is within the Company's available Listing Rule 7.1 capacity (as upsized by an ASX 'super-size' waiver).

New Shares subscribed for under the Institutional Offer are expected to be settled on Wednesday, 12 June 2024 and to be issued on Thursday, 13 June 2024. New Shares issued under the Institutional Offer will rank equally with existing fully paid ordinary shares in Genetic Signatures as at their date of issue.

As announced to ASX on Tuesday, 4 June 2024, the Offer will raise approximately A\$30 million, comprising the Institutional Offer of approximately A\$21.5 million (including the Placement and Institutional Entitlement Offer) and the retail component of the Entitlement Offer (**Retail Entitlement Offer**) of approximately A\$8.5 million. The Entitlement Offer is fully underwritten by Bell Potter Securities Limited and Taylor Collison Limited.

Genetic Signatures expects ASX to lift its trading halt and for Genetic Signatures' ordinary shares to recommence trading on ASX on an ex-entitlements basis from market open today.

Retail Entitlement Offer

The Retail Entitlement Offer is expected to open at 9.00am on Wednesday, 12 June 2024 and close at 5.00pm (Sydney, Australia time) on Monday, 1 July 2024. The despatch of the retail entitlement offer booklet for the Retail Entitlement Offer (**Booklet**) with personalised entitlement and acceptance forms for eligible retail shareholders is scheduled to occur on Wednesday, 12 June 2024.

Eligible retail shareholders with a registered address in Australia or New Zealand will be able to subscribe for 1 New Share for every 5.82 existing ordinary shares held in Genetic Signatures as at 7.00pm (Sydney, Australia time) on the record date of Thursday, 6 June 2024, at the same offer price of A\$0.75 per New Share, being the same as the price paid per New Share by investors in the Institutional Offer.

The terms and conditions under which eligible retail shareholders may apply for New Shares under the Retail Entitlement Offer will be outlined in the Booklet. Copies of the Booklet will be available on the ASX website and our website at from Wednesday, 12 June 2024.

Eligible retail shareholders should confirm the actual number of New Shares issued to them before trading in such shares, and the sale by any eligible retail shareholder of New Shares prior to receiving their holding statement is at their own risk.

Offer Timetable

Event	Time (Sydney time) / Date
Back-to-back trading halt	Friday, 31 May 2024
Offer announcement and Placement and Institutional Entitlement Offer opens	Tuesday, 4 June 2024
Announcement of results of Placement and Institutional Entitlement Offer	Thursday, 6 June 2024

Trading in Genetic Signatures shares resumes on an ex-entitlement basis	Thursday, 6 June 2024
Record Date for determining entitlement for the Entitlement Offer	7.00 pm AEST Thursday, 6 June 2024
Retail Offer Booklet made available and retail Entitlement Offer opens	Wednesday, 12 June 2024
Settlement of Placement and Institutional Entitlement Offer	Wednesday, 12 June 2024
Allotment of New Shares issued under the Placement and Institutional Entitlement Offer	Thursday, 13 June 2024
Normal trading of New Shares issued under the Placement and Institutional Entitlement Offer	Friday, 14 June 2024
Retail Entitlement Offer closing date	5.00pm AEST Monday, 1 July 2024
Settlement of Retail Entitlement Offer	Friday, 5 July 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Monday, 8 July 2024
Normal trading of New Shares issued under the Retail Entitlement Offer	Tuesday, 9 July 2024

Note: The timetable above is indicative only and may be subject to change. All times and dates refer to Sydney time. GSS reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws. In particular, GSS reserves the right to extend the closing date of the Retail Entitlement Offer, to accept late applications under the Retail Entitlement Offer (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice. Any extension of the closing date will have a consequential effect on the issue date of New Shares under the Retail Entitlement Offer.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr Neil Gunn
Director and
Interim Chief Executive Officer
neil.gunn@geneticsignatures.com
 T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares to be offered and sold in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933 (the **US Securities Act**) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States unless they are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Forward looking statements

This announcement contains certain "forward-looking statements" including but not limited to projections, that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements can generally be identified by the use of forward-looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Such forward-looking statements include statements regarding the timetable, conduct and outcome of the Offer and the use of proceeds thereof, statements about the plans, objectives and strategies of the management of Genetic Signatures, statements about the industry and the markets in which Genetic Signatures operates and statements about the future performance of the Genetic Signatures businesses. Indications of, and guidance or outlook on, future earnings or financial position or performance, future earnings and distributions are also forward-looking statements.

Any such statements, opinions and estimates in this announcement speak only as of the date hereof and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance, and estimates. The forward-looking statements contained in this announcement are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Genetic Signatures and its subsidiaries, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. No representation, warranty, or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Genetic Signatures or any of its advisers).

5. Additional Information

5.1 Eligibility of Retail Shareholders

The Retail Entitlement Offer is being offered to all Eligible Retail Shareholders only.

Eligible Retail Shareholders are Shareholders on the Record Date who:

- (a) are registered as holders of Existing Shares;
- (b) have a registered address in Australia or New Zealand as noted on the Company's share register;
- (c) are not in the United States and are not a person (including nominees or custodians) acting for the account or benefit of a person in the United States (to the extent such person holds Existing Shares for the account or benefit of such person in the United States);
- (d) were not invited to participate in the Institutional Entitlement Offer and were not treated as an Eligible Shareholder under the Institutional Entitlement Offer (other than as nominee or custodian, in each case in respect of other underlying holdings); and
- (e) are eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

By making a payment by BPAY® (or in the case of Eligible Retail Shareholders in New Zealand, by electronic funds transfer) you will be taken to have represented and warranted that you satisfy each of the criteria listed above to be an Eligible Retail Shareholder. Nominees, trustees or custodians are therefore advised to seek independent professional advice as to how to proceed.

5.2 Ineligible Shareholders

All Shareholders who do not satisfy the criteria to be Eligible Shareholders, are Ineligible Shareholders. Ineligible Shareholders are not entitled to participate in the Entitlement Offer, unless the Company otherwise determines.

The restrictions upon eligibility to participate in the Entitlement Offer arise because the Company has determined, pursuant to Listing Rule 7.7.1(a) and section 9A(3)(a) of the Corporations Act, that it would be unreasonable to extend the Entitlement Offer to Ineligible Shareholders. This decision has been made after taking into account the number of non-residents in Australia and New Zealand on the Company's share register, the relatively small number and value of New Shares to which those Shareholders would otherwise be entitled and the potential costs of complying with legal and regulatory requirements in the jurisdictions in which the Ineligible Shareholders are located in relation to the Entitlement Offer.

The Company (in consultation with the Joint Lead Managers), in its absolute discretion, may extend the Entitlement Offer to any Shareholder if it is satisfied that the Entitlement Offer may be made to the Shareholder in compliance with all applicable laws. The Company (in consultation with the Joint Lead Managers), in its absolute discretion, reserves the right to determine whether a Shareholder is an Eligible Shareholder or an Ineligible Shareholder. To the maximum extent permitted by law, the Company and the Joint Lead Managers disclaim all liability in respect of such determination.

The price at which the Entitlements of Ineligible Shareholders will be sold is the Offer Price. Accordingly, Ineligible Shareholders will not receive any payment or value as a result of the issue of any of those New Shares they would have been entitled to subscribe for had they been eligible to participate in the Entitlement Offer.

5.3 Allotment, trading and quotation

The Company will apply, for quotation of the New Shares on ASX in accordance with Listing Rule requirements. If ASX does not grant quotation of the New Shares, the Company will repay all Application Monies (without interest).

Trading of New Shares will, subject to ASX approval, occur shortly after allotment. It is expected that allotment of the New Shares under the Retail Entitlement Offer will take place on Monday, 8 July 2024. Application Monies will be held by the Company on trust for Applicants until the New Shares are allotted. No interest will be paid on Application Monies.

Subject to approval being granted, it is expected that the New Shares allotted under the Retail Entitlement Offer will commence trading on a normal basis on Tuesday, 9 July 2024.

It is the responsibility of Applicants to determine the number of New Shares allotted and issued to them prior to trading in the New Shares. The sale by an Applicant of New Shares prior to receiving their holding statement is at the Applicant's own risk. The Company and the Joint Lead Managers disclaim all liability whether in negligence or otherwise (to the maximum extent permitted by law) to persons who trade New Shares before receiving their holding statements, whether on the basis of confirmation of the allocation provided by the Company or the Share Registry or otherwise.

5.4 Reconciliation

In any entitlement offer, investors may believe that they own more existing shares on the record date than they ultimately do. This may result in a need for reconciliation to ensure all Eligible Shareholders have the opportunity to receive their full Entitlement.

The Company may need to issue a small quantity of additional New Shares to ensure all Eligible Shareholders have the opportunity to receive their appropriate allocation of New Shares. The price at which these New Shares would be issued, if required, is the same as the Offer Price.

The Company also reserves the right to reduce the Entitlement or the number of New Shares allocated to Eligible Shareholders or persons claiming to be Eligible Shareholders, if their Entitlement claims prove to be overstated, if they or their nominees/custodians fail to provide information requested to substantiate their Entitlement claims, or if they are not Eligible Shareholders.

5.5 Continuous disclosure

The Company is a "disclosing entity" under the Corporations Act and is subject to regular reporting and disclosure obligations under the Corporations Act and the Listing Rules, including the preparation of annual reports and half yearly reports.

The Company is required to notify ASX of information about specific events and matters as they arise for the purposes of ASX making that information available to the stock markets conducted by ASX. In particular, the Company has an obligation under the Listing Rules (subject to certain exceptions) to notify ASX immediately of any information of which it is or becomes aware which a reasonable person would expect to have a material effect on the price or value of Shares. That information is available to the public from ASX and can be accessed at www.asx.com.au/markets/company/GSS. Some documents are required to be lodged with ASIC in relation to the Company. These documents may be obtained from, or inspected at, an ASIC office.

5.6 No cooling off rights

Cooling off rights do not apply to an investment in New Shares. You cannot withdraw your Application once it has been made.

5.7 Underwriting of the Placement and Entitlement Offer

The Company and the Joint Lead Managers have entered into an Underwriting Agreement pursuant to which the Joint Lead Managers has agreed to manage and fully underwrite the Entitlement Offer.

A summary of the key terms of the Underwriting Agreement is provided on slides 36 to 38 of the Investor Presentation contained in section 4.

The Underwriting Agreement contains certain customary:

- (a) conditions precedent that must be satisfied or waived before the Joint Lead Managers are obliged under the Underwriting Agreement to, among other things, underwrite the Offer;
- (b) representations and warranties relating to the Offer and the Company's operations, in favour of the Joint Lead Managers; and
- (c) undertakings in favour of the Joint Lead Managers including in relation to the conduct of the Offer and business of the Company.

The Underwriting Agreement is subject to generally customary termination events, with the key termination events summarised on slides 36 to 38 of the Investor Presentation. If a Joint Lead Manager terminates the Underwriting Agreement in accordance with its terms, that Joint Lead Manager will be released from its obligations under the Underwriting Agreement.

The Joint Lead Managers will receive:

- in respect of the Placement, a management fee of 3% (plus GST) and a selling fee of 3% of the gross proceeds of the Placement (plus GST); and
- in respect of the Entitlement Offer, a management fee of 3% (plus GST) and an underwriting fee of 3% (plus GST) of the gross proceeds of the Entitlement Offer.

The Joint Lead Managers will also be reimbursed by the Company for certain expenses incurred in relation to the Offer. The Company has also agreed to indemnify the Joint Lead Managers and certain affiliated parties from any losses suffered by those parties in connection with the Offer.

5.8 Rounding of Entitlements

Where fractions arise in the calculation of an Entitlement, they will be rounded down to the nearest whole number of New Shares.

5.9 Capital structure

The proposed capital structure of the Company following the issue of the New Shares in connection with the Placement and Entitlement Offer will be as follows:

Event	Shares	Options
As at the date of this Retail Offer Booklet	186,522,642	7,934,750
On completion of the Placement	194,522,642	7,934,750
On completion of the Entitlement Offer (subject to rounding of Entitlements)	226,571,206	7,934,750

5.10 Effect on control

The Company expects that the Entitlement Offer will not have any material effect on control of the Company.

The holdings of Eligible Retail Shareholders who do not participate in the Retail Entitlement Offer and Ineligible Shareholders will be diluted as a result of the New Shares issued under the Entitlement Offer.

5.11 Impact of underwriting

The number of New Shares that will be allocated to the Joint Lead Managers and any sub-underwriters appointed by the Joint Lead Managers will depend on how many New Shares are taken up under the Retail Entitlement Offer.

If no Eligible Retail Shareholders take up their Entitlements (which the Board considers unlikely), then the Joint Lead Managers will be required to subscribe, or procure subscriptions from others, for the shortfall of New Shares (subject to the terms of the Underwriting Agreement). Based on the number of New Shares that have been taken up under the Institutional Entitlement Offer, the maximum theoretical aggregate increase in voting power of the Joint Lead Managers (or any sub-underwriter) in the Company will be approximately 5.03% (subject to rounding).

5.12 Not financial product or investment

This Retail Offer Booklet and the accompanying Entitlement and Acceptance Form is for information purposes only, is not a prospectus, disclosure document or other offering document under the Corporations Act or any other law and has not been lodged with ASIC. It is also not a financial product or investment advice or a recommendation to acquire New Shares and has been prepared without taking into account your investment objectives, financial circumstances or particular needs. The Retail Offer Booklet should not be considered comprehensive and the Company is not licensed to provide financial product advice in respect of the New Shares. The information contained in this Retail Offer Booklet does not purport to contain all the information that you may require to evaluate a possible application for New Shares, nor does it purport to contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act. It should be read in conjunction with the Company's other periodic statements and continuous disclosure announcements lodged with ASX. Before making an investment decision, you should consider the appropriateness of the information in this Retail Offer Booklet having regard to your own objectives, financial situation and needs and seek legal and taxation advice appropriate to your jurisdiction. If you have any questions about whether you should participate in the Entitlement Offer, you should seek professional financial advice before making any investment decision.

5.13 Withdrawal of the Entitlement Offer

The Company reserves the right to withdraw all or part of the Entitlement Offer and this Retail Offer Booklet at any time, subject to applicable laws, in which case the Company will refund Application Monies in relation to New Shares not already issued in accordance with the Corporations Act and without payment of interest. In circumstances where allotment under the Institutional Entitlement Offer has occurred, the Company may only be able to withdraw the Entitlement Offer with respect to New Shares to be issued under the Retail Entitlement Offer.

To the fullest extent permitted by law, you agree that any Application Monies paid by you to the Company will not entitle you to receive any interest and that any interest earned in respect of Application Monies will belong to the Company.

5.14 Privacy

As a Shareholder, the Company and the Share Registry have already collected certain personal information from you. If you apply for New Shares, the Company and the Share Registry may update that personal information or collect additional personal information. Such information may be used to assess your acceptance of the New Shares, service your needs as a

Shareholder, provide facilities and services that you request and carry out appropriate administration.

To do that, the Company and the Share Registry may disclose your personal information for purposes related to your shareholdings to their agents, contractors or third party service providers to whom they outsource services, in order to assess your Application for New Shares, the Company share register for ongoing administration of that register, printers and mailing houses for the purposes of preparation of the distribution of Shareholder information and for handling of mail, or as otherwise under the *Privacy Act 1988* (Cth).

5.15 Taxation

The taxation consequences of any investment in New Shares will depend upon your particular circumstances. Potential investors must make their own enquiries concerning the taxation consequences of an investment in the Company. Applicants should consult their tax adviser for advice applicable to their individual needs and circumstances. The Company considers that it is not appropriate to give advice regarding the tax consequences of the Offer for each individual Shareholder and recommends that you consult your professional tax adviser. The Company, to the maximum extent permitted by law, disclaims all liability with regard to taxation advice.

5.16 Foreign jurisdictions

This Retail Offer Booklet does not constitute an offer of New Shares in any jurisdiction in which it would be unlawful. In particular, this Retail Offer Booklet may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia and New Zealand. The distribution of this Retail Offer Booklet (including an electronic copy) outside Australia and New Zealand may be restricted by law. If you come into possession of the Retail Offer Booklet, you should observe such restrictions and should seek your own advice on such restrictions. No action has been taken to register or qualify the Retail Entitlement Offer, the Entitlements or the New Shares, or otherwise permit the public offering of the New Shares, in any jurisdiction other than Australia and New Zealand.

New Zealand

The New Shares are not being offered to the public within New Zealand other than to existing Shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.

This Retail Offer Booklet has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013. This Retail Offer Booklet is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

United States

This Retail Offer Booklet has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This Retail Offer Booklet does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this Retail Offer Booklet have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

5.17 Governing Law

This Retail Offer Booklet, the Retail Entitlement Offer and the contracts formed on acceptance of the Entitlement and Acceptance Forms are governed by the laws applicable in New South

Wales, Australia. Each Applicant for New Shares submits to the exclusive jurisdiction of the courts of New South Wales, Australia.

6. Definitions and interpretation

6.1 Defined terms

In this Retail Offer Booklet, the following definitions apply unless the context otherwise requires:

Applicant means an Eligible Retail Shareholder who has submitted a valid Application.

Application means the arranging for payment of the relevant Application Monies in accordance with the instructions in this Retail Offer Booklet and the Entitlement and Acceptance Form.

Application Monies means the aggregate amount payable for the New Shares applied for.

ASIC means the Australian Securities and Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or, where the context requires, the securities exchange operated by it on which Shares are quoted.

Closing Date means the day the Retail Entitlement Offer closes, expected to be 5.00pm (AEST) on Monday, 1 July 2024.

Company means Genetic Signatures Limited (ACN 095 913 205).

Corporations Act means the *Corporations Act 2001* (Cth) (as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73).

Eligible Retail Shareholder has the meaning given in section 5.1.

Eligible Shareholders a Shareholder eligible to participate in the Entitlement Offer (whether under the Institutional Entitlement Offer or the Retail Entitlement Offer).

Entitlement means the right to subscribe for 1 New Share for every 5.82 Existing Shares held by Eligible Shareholders on the Record Date, pursuant to the Entitlement Offer.

Entitlement and Acceptance Form means the entitlement and acceptance form accompanying this Retail Offer Booklet for Eligible Retail Shareholders.

Entitlement Offer means the Institutional Entitlement Offer and the Retail Entitlement Offer.

Entitlement Offer Period means the period commencing on the opening date of the Entitlement Offer, as specified in the 'Offer Key Dates' and ending on the Retail Closing Date.

Existing Shares means the Shares already on issue on the Record Date.

Group means the Company and each of its subsidiaries.

Ineligible Retail Shareholder means a Shareholder who is not an Eligible Retail Shareholder.

Ineligible Shareholder has the meaning given in section 5.2.

Institutional Entitlement Offer means the accelerated institutional component of the Entitlement Offer.

Institutional Investor means:

- (a) if in Australia, an "exempt investor" as defined in *ASIC Corporations (Non-Traditional Rights Issue) Instrument 2016/84*, which for the avoidance of doubt includes:
 - (i) an investor to whom an offer of securities does not need disclosure under Part 6D.2 pursuant to section 708(8) of the Corporations Act;

- (ii) a 'professional investor' pursuant to section 708(11) of the Corporations Act; and
- (iii) investors pursuant to section 708(10) of the Corporations Act; or
- (b) in any other case an institutional or professional investor to whom offers of New Shares may lawfully be made in a jurisdiction outside of Australia without the need for a lodged prospectus or other disclosure document or other lodgement, registration, filing with or approval by a government agency.

Institutional Shareholder means a Shareholder on the Record Date who is an Institutional Investor.

Institutional Results Announcement means the ASX announcement released to ASX on Thursday, 6 June 2024 announcing the results of the Institutional Entitlement Offer, which is set out in section 4.

Investor Presentation means the presentation released by to ASX on Tuesday, 4 June 2024, which is set out in section 4.

Launch Announcement means the ASX announcement released to ASX on Tuesday, 4 June 2024 in connection with the Offer, which is set out in section 4.

Joint Lead Managers means Bell Potter Securities Limited ACN 006 390 772 and Taylor Collison Limited ACN 008 172 450.

Listing Rules means the official listing rules of ASX.

New Shares means Shares to be allotted and issued under the Entitlement Offer and Placement.

Offer means the Entitlement Offer and Placement.

Offer Price means \$0.75 per New Share.

Placement means a placement of New Shares to Institutional Investors at the Offer Price.

Record Date means 7.00pm (AEST) on Thursday, 6 June 2024.

Retail Entitlement Offer means retail component of the Entitlement Offer to which this Retail Offer Booklet relates.

Retail Offer Booklet means this document.

Share means a fully paid ordinary share in the capital of the Company.

Share Registry means Boardroom Pty Limited ACN 003 209 836.

Shareholder means a holder of Shares.

Underwriting Agreement means the underwriting agreement dated 4 June 2024 between the Company and the Joint Lead Managers.

US Securities Act means the US Securities Act of 1933.

6.2 Interpretation

In this Retail Offer Booklet, the following rules of interpretation apply unless the context otherwise requires:

- (a) the singular includes the plural and the plural includes the singular;

- (b) other parts of speech and grammatical forms of a word or phrase defined in this Retail Offer Booklet have a corresponding meaning;
- (c) a reference to a section or a paragraph is a reference to a section or a paragraph of this Retail Offer Booklet;
- (d) a reference to “dollars” or “\$” is to Australian currency; and
- (e) words and phrases not specifically defined in this Retail Offer Booklet have the meaning given to them in the Corporations Act and a reference to a statutory provision is to the Corporations Act unless otherwise specified.

7. Corporate information

Company

Genetic Signatures Limited ACN 095 913 205
7 Eliza Street
Newtown NSW 2042
Australia

Directors

Nickolaos Samaras	Non-Executive Chair
Neil Gunn	Interim CEO and Director
Mike Aicher	Executive Director
Anthony Radford	Non-Executive Director
Caroline Waldron	Non-Executive Director
Stephane Chatonsky	Non-Executive Director

Joint Lead Managers

Bell Potter Securities Limited
ACN 006 390 772
Level 29, 101 Collins Street
Melbourne VIC 3000

Taylor Collison Limited
ACN 008 172 450
Level 16, 211 Victoria Square
Adelaide, South Australia 5000

Share Registry

Boardroom Pty Limited
Level 8, 210 George Street
Sydney, NSW 2000

Legal Adviser

Hamilton Locke
Level 48, 152-158 St George Terrace
Perth, WA 6000